UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                   FORM 10-KSB
(Mark One)

[X]     ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
        OF 1934

                   For the fiscal year ended September 30, 2003

[ ]     TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
        ACT OF 1934

       For the transition period from           to
                                    -----------    -------------

                        Commission file number 000-21914

                            HEALTHRENU MEDICAL, INC.
        ---------------------------------------------------------------
        (Exact name of small business issuer as specified in its charter)

               NEVADA                                    84-1022287
  (State or other jurisdiction of           (IRS Employer Identification No.)
   incorporation or organization)

        307 South Friendswood Drive, Suite E-1, Friendswood, Texas 77546
                -------------------------------------------------
                    (Address of principal executive offices)

                                 (281) 996-8100
                        -------------------------------
                        (Registrant's telephone number)

Securities registered under Section 12(b) of the Exchange Act:

                                      NONE

Securities registered under Section 12(g) of the Exchange Act:

                    COMMON STOCK, $.001 PAR VALUE PER SHARE

     Check whether the registrant (1) has filed all reports  required to be
filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or
for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing  requirements  for the past 90 days. Yes
[X] No [ ]

     Check if there is no disclosure of delinquent filers in response to Item
405 of Regulation S-B not contained in this form, and no disclosure  will be
contained, to the best of the registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this Form 10-KSB
or any amendment to this Form 10-KSB. [ ]

     The issuer's revenues for the most recent fiscal year ended September 30,
2003 were $26,281.

     The aggregate market value of the issuer's voting and non-voting common
equity held by non-affiliates computed by reference to the average bid and ask
price of such common equity as of January 13, 2004, was approximately
$48,135,888.

     As of January 13, 2004 the issuer had 19,499,364 shares of common stock,
$.001 par value per share outstanding.

                    Documents Incorporated by Reference: NONE

          Transitional Small Business Disclosure Format: Yes [ ] No [X]

                                      -1-
<PAGE>


                            HEALTHRENU MEDICAL, INC.
                                  FORM 10-KSB
                          YEAR ENDED September 30, 2003
                                      INDEX

                                     Part I

    Item 1.             Description of Business                              3

    Item 2.             Description of Property                              6

    Item 3.             Legal Proceedings                                    7

    Item 4.             Submission of Matters to a Vote of
                        Security Holders                                     7


                                     Part II

    Item 5.             Market for Common Equity and Related
                        Stockholder Matters                                  7

    Item 6.             Management's Discussion and Analysis or
                        Plan of Operation                                    9

    Item 7.             Financial Statements                                F-1

    Item 8.             Changes in and Disagreements with
                        Accountants on Accounting and Financial
                        Disclosure                                           14

    Item 8A.            Controls and Procedures                              15


                                    Part III

    Item 9.             Directors, Executive Officers, Promoters
                        and Control Persons; Compliance with
                        Section 16(a) of the Exchange Act                    16

    Item 10.            Executive Compensation                               17

                                      -2-
<PAGE>

    Item 11.            Security Ownership of Certain Beneficial
                        Owners and Management and Related Stockholders
                        Matters                                              18

    Item 12.            Certain Relationships and Related
                        Transactions                                         18

    Item 13.            Exhibits and Reports on Form 8-K
                        (a)   Exhibits                                       19

                        (b)   Reports on Form 8-K                            21

    Item 14.          Principal Accountant Fees and Services                 21

    Signatures                                                               22


                                     PART I

ITEM 1.  DESCRIPTION OF BUSINESS

                SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain  statements  in  this Annual Report on Form 10-KSB (this "Form 10 KSB"),
including  statements  under  "Item  1.  Description  of Business," and "Item 6.
Management's  Discussion  and Analysis", constitute "forward looking statements"
within the meaning of Section 27A of the Securities Act of 1934, as amended, and
the  Private Securities Litigation Reform Act of 1995 (collectively, the "Reform
Act").  Certain, but not necessarily all, of such forward-looking statements can
be  identified  by  the  use  of forward-looking terminology such as "believes",
"expects", "may", "will", "should", or "anticipates", or the negative thereof or
other  variations  thereon  or  comparable  terminology,  or  by  discussions of
strategy  that  involve risks and uncertainties. Such forward-looking statements
involve known and unknown risks, uncertainties and other factors which may cause
the  actual  results,  performance  or  achievements of HealthRenu Medical, Inc.
("HealthRenu",  "the  Company",  "we", "us" or "our") to be materially different
from  any  future  results,  performance or achievements expressed or implied by
such  forward-looking statements. References in this form 10-KSB, unless another
date  is  stated,  are  to  September  30,  2003.

BUSINESS DEVELOPMENT

HealthRenu Medical, Inc. (the "Company") was originally incorporated in Colorado
as  American  Merger  Control,  Inc.  on  January  6, 1986. In 1990, the Company
changed  its  name to Ultratech Knowledge Systems, Inc., and in 1993 the Company
changed  its  name  again  to  AGTsports,  Inc.  During  the  fiscal years ended
September  30,  1991 and through September 30, 1998, the Company's business plan
was  to pursue providing technological and software services to golf and related
industries. In 1998, the Company abandoned this business plan. Prior to entering
into  an  Exchange  Agreement,  discussed  below,  and  the  consummation of the
transactions thereunder, the Company was considered a "shell" (or "blank check")
company  whose  sole  purpose  was  to  search  for  and enter into new business
opportunities.

                                      -3-
<PAGE>

On  September  4,  2003,  the Company merged into AGTsports, Inc., the Company's
wholly-owned  Nevada  subsidiary.  As  a  result  of the merger, the Company was
reincorporated  in  Nevada.

On September 26, 2003, AGTsports, Inc., Health Renu, Inc, a Delaware corporation
(hereinafter "Health Renu") and the former Health Renu Shareholders entered into
an  Exchange  Agreement  whereby Health Renu became a wholly-owned subsidiary of
the  Company  and  control  of  the  Company  shifted  to the former Health Renu
Shareholders.

The  exchange agreement represented a recapitalization of Health Renu, Inc. with
accounting  treatment similar to that used in a reverse acquisition, except that
no goodwill or intangible asset is recorded. A recapitalization is characterized
by  the  merger of a private operating company into a non-operating public shell
corporation  with  nominal  net  assets  and typically results in the owners and
managers  of the private company having effective or operating control after the
transaction.  The  Company  emerged  as the surviving financial reporting entity
under  the  agreement, but AGTSports, Inc. (which changed its name to HealthRenu
Medical,  Inc.)  remained  as  the  legal  reporting  entity.

For  the  last  three (3) years and since its inception, Health Renu has been in
the  medical  research  and  development  stage,  with  a  focus on creating and
improving  its skin care and wound care products. During this three-year period,
Health  Renu  had  very  little  production  or  revenue.  As  a  result  of the
acquisition  of  Health Renu and a change in business focus, the Company changed
its  name  to  HealthRenu  Medical, Inc. Hereinafter, a reference to the Company
includes  a  reference  to Health Renu and vice-versa unless otherwise provided.

BUSINESS OF THE ISSUER

The  Company  is a biotechnology company that develops, produces and distributes
proprietary  products  for  personal  skin  care and wound care under the Health
Renu'(R)  brand  name.  The  products  are all natural and provide nutrients and
proteins  which  may  aid  the  body  in  its  healing  process.

PRINCIPAL PRODUCTS

The Company has developed a product line (the "Product Line" or "Finished
Products") consisting of the following eight (8) products:

     DERM-ALL GEL
     Used for non-healing wounds, pressure ulcers, diabetic ulcers, and surgical
     wounds.

     SKIN RENU PLUS
     Used  for  diabetic  neuropathy, circulation, skin prep for pre-opt surgery
     patients,  used in post-opt surgical wound care for preventive care against
     possible  staph infection and more rapid recovery and scar reduction of the
     wound  site.

     SKIN RENU LOTION
     Diabetic  preventive  skin  care, preventive skin care for pressure ulcers,
     dermatitis,  eczema, age spots, chronic bruising associated with thin skin,
     skin  condition  for  thin  skin,  chronic  dry  skin,  cracked  hands, and
     preventive  care  against  latex  allergies.

                                      -4-
<PAGE>

     SKIN RENU
     Used  for age spots, bruising, and burns. Important for people with serious
     allergic  reactions  to  insect  bites.

     RENU CARE
     Used as a non-rinse cleanser for bed patients, provides skin protection and
     can  be  used  for  stage  1  pressure  ulcers  (bedsores).

     DEEP RELIEF
     Has  the transdermal ability to penetrate through skin layers, transferring
     anti-inflammatory ingredients through muscle tissue to the inflamed joints.
     Made  with  a  heat  action  and  used  for  severe  arthritis.

     HEALTH RENU SPORTS MEDICINE
     Has  the transdermal ability to penetrate through skin layers, transferring
     anti-inflammatory ingredients through muscle tissue to the inflamed joints.
     Made  with  peppermint oil which gives a peppermint fragrance as well as an
     anti-inflammatory  action.  Made  with  more  of  a  mild  heat  action.

     FACIAL SOAP
     Used  for  facial skin disorders-contains omega 3,6 & 9 fatty acids as well
     as  vitamins.

DISTRIBUTION

The Company distributes its products directly to consumers and to nursing homes,
surgery  centers,  pharmacies  and  other  medical markets throughout the United
States. The products are registered for such sale and distribution by the United
States  Federal  Drug  Administration  (the  "FDA"). Most of the Company's sales
revenue  is from sales of its products directly to consumers. Historically, most
of  the  Company's sales had been to consumers, nursing homes, home health care,
pharmacies,  smaller  medical  supply  companies, family clinics, and orthopedic
surgeons,  with  some  sales  to  hospitals.

COMPETITION

The market for healthcare products is estimated at 150 billion dollars, of which
the  Company  has  acquired  less  than  one-percent  (1%) market share with its
Product  Line.  The  Company  will  depend  on marketing efforts to increase its
market share. The Company believes that with an aggressive marketing campaign it
can quickly generate more revenue and establish its Product Line nationwide. The
Company's  cost  for research and development is fully paid. The Company intends
to  spend  approximately  40% of its resources to increase its market share over
the  next  twelve  months.

The  Company  plans  to  compete based on the effectiveness of its products. The
Company's  products  are effective and work better than similar products offered
by  competitors.  The  Company intends to operate with minimal overhead costs by
outsourcing  its  shipping,  receiving,  purchasing,  and  production functions.

                                      -5-
<PAGE>

SOURCES  AND  AVAILABILITY  OF  ESSENTIAL  INGREDIENTS

The  Company  has  developed  multiple  sources  for  the  supply  of  essential
ingredients  used  in  its  products.  The  Company  has secured access to these
ingredients at all phases of product development. The Company believes that this
access  will allow the Company to react quickly to demand as well as cultivate a
long-term,  quantifiable  supply  of  its  products.

DEPENDENCE  ON  ONE  OR  A  FEW  CUSTOMERS

The Company does not currently depend on any one or a few customers.

INTELLECTUAL PROPERTY

The Company owns the registered trademark, Health Renu'(R). The Company does not
hold  any  patents  or  licenses.

NEED FOR GOVERNMENT APPROVAL

The Company has satisfied FDA requirements with respect to its finished products
for  sales directly to consumers and medical related companies. The products are
considered over the counter products ("OTC").  The Company is currently
developing new  OTC products for which it will need to meet FDA requirements in
order to sell  these  products to consumers and medical related companies. All
production of products  is  outsourced  to  FDA  certified  labs.

RESEARCH AND DEVELOPMENT OVER PAST TWO YEARS

The  Company  is continually developing new products to aid in personal skin and
wound  care  for  its customers. Research and development is an integral part of
the Company and is conducted on an on-going basis. As new products are developed
and  tested,  they  will  continually  be  brought  to  the  market. The Company
estimates  that  it  has  spent  $1,090  and  $50,354 for the fiscal years ended
September  30,  2002  and  September  30,  2003,  respectively, for research and
development.

Dr.  Dan  Sparks MD-surgeon, is completing a clinical write-up of the use of the
products  for  pre-opt  &  post-opt  surgical  wound care. The write-up covers a
two-year period of time that has resulted in the design of two new products that
will  be  stated  in  the  write-up.  Dr.  Sparks began his work in 2001. At the
present  time,  Dr. Sparks' work is continuing and ongoing. The Company paid Dr.
Sparks  200,000  shares  as  compensation  for  his  services.

EMPLOYEES

The  Company  has  three  (3)  full-time  employees.  The Company contracts with
consultants  to  assist  in  numerous  areas  of  the  Company's  operations and
development. Additionally, the Company outsources key functions to control costs
and keep its overhead low. The Company will hire other full-time employees on an
as  needed  basis.

ITEM 2.  DESCRIPTION OF PROPERTY

The  Company  has  an  office  at  307  South  Friendswood  Drive,  Suite  E-1,
Friendswood,  Texas 77546. Friendswood is a suburb located Southeast of Houston,
Texas.  The  Company has entered into a one (1) year lease for 1,300 square feet
of  office  space  for  the  Friendswood  office. The lease provides for monthly
payments  of  $1,300.

Effective  April  30,  2002  the Company entered into a lease agreement with the
father  of  the President and major stockholder of the Company to lease 33 acres
of  land  in  Rosebud,  Texas to be used in the production of raw materials. The
lease  payments  are  $250  per month for ten years. As of September 30, 2003 no
lease  payments were made, and included in accounts payable is $4,250 related to
this  lease.

                                      -6-
<PAGE>

ITEM 3.  LEGAL PROCEEDINGS

As  of  the  date  of filing of this report, the Company was not a party to, nor
aware  of,  any  legal  proceedings  involving  the  Company.

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

Prior  to  the recapitalization in September 2003, a majority of shareholders of
the AGTsports, Inc., via written consent to action without a meeting of the
shareholders,  approved  a  name  change  to  HealthRenu Medical, Inc., an 850:1
reverse  stock  split, and reauthorization of 50,000,000 shares of common stock.
The  number of shares consenting to the action was 77,751,513 out of 113,847,314
pre-split eligible to vote.

Prior  to  the  recapitalization  in  September  2003, the majority Series 2000A
preferred  shareholders, via written consent, without a meeting, approved an
850:1 reverse stock split of the preferred shareholders and a conversion of
the Series 2000A preferred stock  following  the  reverse  stock  split  into
common stock on a one for one basis.

Prior  to  the recapitalization in September 2003, a majority of shareholders of
the  Company,  via  signed written consent approved a Plan of Merger whereby the
Company  merged  into  its  wholly-owned  Nevada  subsidiary,  and  thus,  was
reincorporated  in  Nevada.  There  were 81,797,905 votes for, and 243,900 votes
against,  the  Plan  of  Merger  out  of a total of 113,847,314 pre-split votes.


                                     PART II

ITEM 5.  MARKET FOR COMMON EQUITY AND RELATED STOCKHOLDER MATTERS

"Bid"  and  "asked"  offers  for  the  common  stock  are  listed  on the NASDAQ
OTC-Bulletin  Board published by the National Quotation Bureau, Inc. The trading
symbol  for  the common stock was "AGTP" and was changed to "HRUM" in connection
with  the  Company's  name  change  on  September  15,  2003.

The  following  table  sets  forth the high and low bid prices for the Company's
common  stock  for  the periods indicated as reported by the NASDAQ OTC-Bulletin
Board.  The  quotations  are  believed  to  reflect inter-dealer prices, without
retail  mark-up,  mark-down  or  commissions  and  may  not  represent  actual
transactions.

<TABLE>
<CAPTION>


                                             Bid Prices

Quarter Ended                      High                       Low
------------------                 -----                      -----
<S>                                                  <C>    <C>
September 30, 2003                 0.65                        0.01
June 30, 2003                      0.65                        0.01
March 31, 2003                     0.01                        0.01
December 31, 2002                  0.01                        0.003
September 30, 2002                 0.005                       0.001
June 30, 2002                      0.01                        0.005
March 31, 2002                     0.03                        0.01
December 31, 2001                  0.01                        0.005
September 30, 2001                 0.02                        0.001
</TABLE>

                                      -7-
<PAGE>

There  were  964 holders of record of the common stock as of September 30, 2003.
The  Company  has  never  paid  a cash dividend on its common stock and does not
anticipate the payment of a cash dividend in the foreseeable future. The Company
intends  to  reinvest in its business operations any funds that could be used to
pay a cash dividend. The Company's common stock is considered a "penny stock" as
defined  in  certain  rules  (the  "Rules") under the Securities Exchange Act of
1934. In general, a security which is not quoted on NASDAQ or has a market price
of less than $5 per share where the issuer does not have in excess of $2,000,000
in  net  tangible  assets  (none  of  which  conditions  the  Company  meets) is
considered  a  penny  stock.  The  SEC's  rules  regarding  penny  stocks impose
additional  sales  practice  requirements  on  broker-dealers  who  sell  such
securities  to persons other than established customers and accredited investors
(generally  persons  with  net worth in excess of $1,000,000 or an annual income
exceeding  $200,000  or  $300,000  jointly  with their spouse). For transactions
covered  by  the  rules,  the  broker-dealer  must  make  a  special suitability
determination for the purchaser and receive the purchaser's written agreement to
the  transaction  prior  to  the  sale.  Thus  the  Rules  affect the ability of
broker-dealers to sell the Company's shares should they wish to do so because of
the  adverse  effect  that the Rules have upon liquidity of penny stocks. Unless
the  transaction  is  exempt  under  the Rules, under the Securities Enforcement
Remedies  and  Penny Stock Reform Act of 1990, broker-dealers effecting customer
transactions  in penny stocks are required to provide their customers with (i) a
risk  disclosure  document; (ii) disclosure of current bid and ask quotations if
any;  (iii)  disclosure  of  the compensation of the broker-dealer and its sales
personnel  in  the  transaction; and (iv) monthly account statements showing the
market  value of each penny stock held in the customer's account. As a result of
the  penny  stock rules the market liquidity for the Company's securities may be
severely  adversely  affected  by limiting the ability of broker-dealers to sell
the  Company's  securities  and  the  ability of purchasers of the securities to
resell  them.

RECENT SALES OF UNREGISTERED SECURITIES

On September 26, 2003, the Company issued 15,447,699 shares of its common stock,
$.001  par value per share (the "Common Stock"), which were not registered under
the  Securities  Act  of  1933,  as amended (the "Act"), pursuant to an Exchange
Agreement  whereby  Health Renu became a wholly-owned subsidiary of the Company.
The  number  of  shares  issued excludes the conversion of $379,902 of notes and
accrued  wages  into  379,902 shares of Common Stock that were issued during the
fiscal  year  ending  September  30, 2004. The Company claims the exemption from
registration  afforded  by  Rule  506  of  Regulation  D  under  the  Act.

Prior  to  the  recapitalization,  AGTsports,  Inc.  amended  its  Articles  of
Incorporation  on  August  1,  2003, to authorize 500,000 shares of Series 2003A
Preferred Stock, $.001 par value per share. The Series 2003A Preferred Stock was
designated  with 125 votes per share entitling the holder thereof to vote on all
shareholder  matters  at  any  meeting of the shareholders of AGTsports, Inc. On
that  same  date, the Board of Directors issued all 500,000 shares of the Series
2003A  Preferred  Stock  to  Randy  Mullins  as  a  signing bonus pursuant to an
employment  agreement  under  which Mr. Mullins will serve as Chairman and Chief
Executive  Officer of the Company. Mr. Mullins subsequently returned all 500,000
shares  of Series 2003A Preferred Stock to the Company, which in turn, cancelled
the  same. The Company claims an exemption from registration afforded by Section
4(2) of the Act since the foregoing issuances did not involve a public offering,
the  recipients  took  the  shares for investment and not resale and the Company
took  appropriate  measures to restrict transfer. No underwriters or agents were
involved in the foregoing issuances and no underwriting discounts or commissions
were  paid  by  the  Company.

                                      -8-
<PAGE>

In November and December of 2003, the Company issued 450,000 shares of
restricted Common Stock to Randy Mullins for  joining the Company as chief
executive officer and 50,000 restricted shares in  cancellation  for a note
payable. On January 12, 2004, the Company issued an aggregate of 187,500 shares
of restricted Common Stock to Randy Mullins for his services  as chief executive
officer pursuant to his employment contract through December 31,  2003.  The
shares were not registered under the Securities Act of 1933,  as amended
(the "Act"). The Company claims an exemption from registration afforded by
Section  4(2)  of  the  Act  since the foregoing issuances did not involve a
public offering, the recipient has access to information that would be
included  in  a  registration  statement, took the shares for investment and not
resale  and  the  Company  took  appropriate  measures  to  restrict  transfer.

On  August  28, 2000 the board of directors authorized the issuance of 1,500,000
shares  of  "Series 2000A" convertible preferred stock with a par value of $.001
per  share.  Each  share  is convertible at the option of the shareholder to one
share  of  Common  Stock.  Shares of the Series 2000A automatically
convert  to  common  shares  upon  the closing of a firm commitment underwritten
public  offering  with  net  proceeds  in  excess  of  $2,000,000  or  a vote of
two-thirds of the Series 2000A preferred shareholders. As of September 30, 2003,
there  were  1,763  (or  1,498,395  pre-1:850 reverse split) shares outstanding.
The Company claims an exemption from registration afforded by Section 4(2) of
the Act since the foregoing issuances did not involve a public offering, the
recipients took the  shares  for  investment  and  not  resale  and the
Company took appropriate measures  to  restrict  transfer. No underwriters or
agents were involved in the foregoing  issuances  and  no underwriting discounts
or commissions were paid by the Company.

ITEM 6.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

This  report  contains  forward looking statements within the meaning of Section
27a of the Securities Act of 1933 and Section 21e of the Securities Exchange Act
of  1934.  These  forward  looking  statements  are subject to certain risks and
uncertainties  that  could  cause  actual  results  to  differ  materially  from
historical  results  or  anticipated  results,  including  those set forth under
"Factors  that  may  affect  future results" in this Management's Discussion and
Analysis of Financial Condition and Results of Operations" and elsewhere in this
report. The following discussion and analysis should be read in conjunction with
"Selected  Financial  Data"  and  the  Company's  financial statements and notes
thereto  included  elsewhere  in  this  report.

                                      -9-
<PAGE>

OVERVIEW

On  September  26,  2003, the Company acquired 100% of the outstanding shares of
Health  Renu  pursuant  to  an  Exchange  Agreement. As a result of the Exchange
Agreement,  Health  Renu  became a wholly-owned subsidiary of the Company,
control  of  the  Company shifted to the former Health Renu Shareholders and the
Company changed its name to HealthRenu Medical, Inc. For the last
three  (3)  years  and  since its inception, Health Renu has been in the medical
research and development stage, with a focus on creating and improving it's skin
care  and  wound  care products. During this period, Health Renu had very little
production  or  revenue.  Due  to  a  combination  of an overwhelmingly positive
response  from  users  of the Company's products, increased access to healthcare
providers  and  an  aggressive marketing plan, the Company anticipates increased
sales  during  the  next  fiscal  year.

The Company's management estimates that the wound care industry is a six billion
dollar  a  year  industry.  The  wound  care  industry  consists  primarily  of
maintaining non-healing wounds (i.e., wounds that do not heal). According to the
2000 U.S. Census, someone in the U.S. turns 50 years of age every seven seconds.
The  50  year  and  older age group is the fastest growing age group in the U.S.
With  that  age group come various types of skin disorders, non-healing diabetic
ulcers,  diabetic  neuropathy,  pressure  ulcers,  arthritis,  heart disease and
surgery.  A  high  number  of 50 to 60 year olds have aging parents that live in
nursing  homes.  The  elderly  are  living  longer lives, but at a high cost for
medical  care.

Medicare  or  Medicaid cover some of cost of providing non-healing wound care to
senior citizens who are covered by those programs. In the context of non-healing
wound  care  provided  by  institutional  healthcare  providers,  the  Company's
products are currently not specifically reimbursable by insurance companies, but
are  classified  as  costs  associated  with  providing services to the patient.

Approximately  28  million  U.S.  households have taken on the responsibility to
care  for  aging  parents.  Many  of  the  problems  they face in taking on this
responsibility  concern  skin  care, circulation and arthritis. Due to aging and
poor  immune  systems,  the  body  loses  its  ability to maintain production of
certain  fatty  acids  and  amino acids that are critical for maintaining normal
body  function.  Due to this problem, there are very few medical treatments that
have  any  affect  in  treating  skin  diseases  of  the elderly and many of the
treatments  that  seem  to  have  some  success  also have serious side effects.

The  Company  believes  that  its  products  have  a positive effect in treating
certain skin conditions, especially those of the elderly with little or no known
side  effects.  All  of  the Company's products use omega-3, omega-6 and omega-9
essential  fatty  acids.  These  essential fatty  acids  contained in the
Company's  products are recognized  by the body as natural substances. When
treating wounds or providing care  of  the  skin,  essential  fatty acids
increase blood flow to the affected areas.  When blood flow increases, it aids
the body's natural ability to heal, providing  a  positive  response  to  the
affected  area. These essential fatty acids are readily  absorbed by the body.
The body uses these ingredients to aid in healing and  does not fight them off
as foreign. The Company anticipates that a clinical study will be published on
the positive effects of its product's, however, there is  currently  no
such  published  report.

                                      -10-
<PAGE>

MARKETING STRATEGY

The  Company's  products  are  currently  used for skin care and wound care. The
Company's  products  are  used  for  diabetic  skin  care,  diabetic neuropathy,
circulation, non-healing wounds, various types of skin disorders, and arthritis.
The  Company  is aggressively pursuing additional uses for its products in other
areas  of  the  medical field. For example, the Company is researching using its
products as transdermal carriers of other medications into the body, which would
result  in  many  different  applications  for  the  Company's  products.

Most  of  the  Company's sales revenue is from sales of its products directly to
consumers.  Historically,  most  of  the Company's sales have been to hospitals,
walk-in  clinics  and nursing homes in the area of emergency, non-healing wounds
of  the  human  body such as staph infections, diabetic ulcers, and amputations.
The  Company  intends to pursue other business opportunities that compliment its
products.

Most of the Company's sales as a result of test marketing have been to household
consumers, nursing homes, home health care, family clinics, pharmacies, surgeons
and  some  hospital  sales.  The  Company  has  completed  the  production of TV
commercials  to  advertise  its  products.  The  Company  will  begin to air the
commercials  in  2004.  The Company's management expects that the TV commercials
will  provide not only an increase in sales, but also name brand recognition for
the  products  in  preparation  for  placing the products into drugstore chains.

COMMITMENTS FOR CAPITAL EXPENDITURES

The Company currently has sufficient raw material to produce inventory.  Lab
costs associated with the  production  of  this  inventory  are  approximately
$150,000 for which the Company  will  need  external  financing.

COMPARISON OF OPERATING RESULTS

FISCAL YEAR ENDED SEPTEMBER 30, 2003 ("2003") COMPARED TO FISCAL YEAR ENDED
SEPTEMBER 30, 2002 ("2002")

The  Company experienced a substantial decrease in sales of $52,221 (or 67%) for
the  fiscal  year ended September 30, 2003 to $26,281 as compared to $78,502 for
the fiscal year ended September 30, 2002. During the fiscal year ended September
30,  2003, the Company was primarily focused on expansion. The decrease in sales
was  due  to  the Company's use of available capital for expansion purposes. The
Company  established  its  corporate offices in Houston, Texas. The Company used
funds to accomplish the recapitalization discussed in Note 1 to the accompanying
financial statements. The Company would have ordinarily allocated the funds that
it  used  for  the  recapitalization  to  promote  the  Company's  products.

Gross  profit for the fiscal year ended September 30, 2003 decreased $19,647 (or
110%)  to a negative $1,774 compared to a positive $17,873 for the fiscal year
ended  September  30, 2002. Gross profit as a percentage of sales ("gross profit
margin")  decreased to nil for the fiscal year ended September 30, 2003 from 23%
for  the  fiscal year ended September 30, 2002. The decrease was attributable to
the  significant  decrease  in sales and a higher proportion of cost of sales to
sales.

                                      -11-
<PAGE>

General  and  administrative ("G&A") expenses were $444,910 and $110,258 for the
years  ended  September  30, 2003 and 2002, respectively. The increase in G&A is
also  due  to  the Company's expansion efforts. The Company added administrative
personnel  to  assist  in  managing  the  anticipated growth of the Company. The
Company  hired  experienced  senior  management  personnel  to  provide  for the
anticipated  growth.

The  Company  incurred  $561,982  of  expense,  which  included  stock-based
compensation  of  $487,500,  related  to  the  Company's  recapitalization  in
September,  2003.

Interest  expense decreased to $698 for the fiscal year ended September 30, 2003
from  $3,465  for  the  fiscal  year  ended  September 30, 2002. The Company has
$16,403  of  notes  payable  to  stockholders, discussed below. The Company pays
approximately 10% interest  on  these  notes.

As  of September 30, 2003, the Company had an accumulated deficit of $1,323,922.

LIQUIDITY AND CAPITAL RESOURCES

For  the  year  ended  September 30, 2003 the Company has not generated positive
cash  flow  from  its  own  operations  due  to  the  preliminary nature of such
operations,  its  ongoing  investment in research and development and its recent
expansion. Consequently, the Company has been dependent on external financing to
fund  its  cash  requirements.

As  of  September 30, 2003, the Company's cash totaled $17,684 and total current
assets  were  $75,358. Inventory at September 30, 2003 was $46,903 consisting of
$31,841  of  work-in-progress  and  $15,062  of  finished  goods.

As  of  September  30,  2003,  the Company's accounts payable totaled $78,004 of
which  $17,500  was  accrued  pursuant  to a consulting agreement and $4,250 was
accrued  pursuant  to  a  related  party lease agreement, discussed below. Total
current  liabilities  were  $98,242,  of  which  $16,403  were  notes payable to
stockholders.

It  is imperative that the Company raise capital to implement its business plan.
The  Company  will  require  approximately  $500,000  of additional financing to
implement its business plan. At this time, no such additional financing has been
secured  or  identified.  If  the Company is unable to obtain debt and/or equity
financing upon terms that management deems sufficiently favorable, or at all, it
would  have a materially adverse impact upon the Company's ability to pursue its
aggressive  marketing  strategy  and  maintain  its  current operations. Without
additional  capital  funding, the Company believes it cannot continue to operate
in  2004  and  could  not expand or meet its business objectives. If the Company
does  not receive external financing, its revenue stream would not expand, would
likely  decrease  and  significant  opportunities would be lost which would be a
limiting  factor on the Company's growth. In the event that the Company does not
receive  external  financing,  the  Company's  management  would  streamline the
business  to  exist  on  the  available  cash  flow.

The  Company  is  currently  exploring  all  opportunities  to raise the capital
necessary  to  develop  it  business  operations.

There can be no assurance that any new capital would be available to the Company
or  that adequate funds for the Company's operations, whether from the Company's
revenues, financial markets, or other arrangements will be available when needed
or  on  terms  satisfactory  to the Company. The Company has no commitments from
officers, directors or affiliates to provide funding. The failure of the Company
to  obtain  adequate  additional  financing  may  require  the Company to delay,
curtail  or  scale  back some or all of its operations, sales, marketing efforts
and  research  and  development  programs.  Any additional financing may involve
dilution  to  the  Company's  then-existing  shareholders.

                                      -12-
<PAGE>

RISK FACTORS

Dependence  Upon  External  Financing.  It is imperative that the Company raise
capital  to  expand  its  operations  and stay in business. The Company requires
capital of approximately $500,000 to implement its business plan. If the Company
is  unable to obtain debt and/or equity financing upon terms that its management
deems  sufficiently  favorable,  or  at  all, it would have a materially adverse
impact  upon  the Company's ability to pursue its business strategy and maintain
its  current  operations.

Even if Product is Successful, The Company May Be Unable to Sell Its Product. In
the event that the Company is successful in completing its product, there can be
no  assurance  that  the  Company  will  be able to sell its products at all, or
enough  at  quantities and prices  needed  to  maintain  operations.

Risk of Conflict With Respect to Purchase of Raw Materials.  The Agricultural
Research Group (hereinafter "ARG"), of which Darrell Good, the Company's
President, is a beneficial owner, is planning to supply the Company with raw
materials for the Company's products. This may impose a conflict as Mr. Good has
an  interest  in both ARG and the Company with the risk that the Company may not
receive  the  best  possible  price for such raw materials. As a director of the
Company Mr. Good is bound by a duty of loyalty which requires that directors act
in  good faith and not allow personal interests to override the interests of the
Company  and  its  stockholders  as  a  group.

                                      -13-

<PAGE>

ITEM 7.  FINANCIAL STATEMENTS

The financial statements of the Company as audited by Ham, Langston & Brezina,
LLP, are  enclosed  herein.


                            HEALTHRENU MEDICAL, INC.





                              FINANCIAL STATEMENTS
                     WITH REPORT OF INDEPENDENT ACCOUNTANTS
                AS OF SEPTEMBER 30, 2003 AND FOR THE YEARS ENDED
                           SEPTEMBER 30, 2003 AND 2002



<PAGE>


                            HEALTHRENU MEDICAL, INC.
                                TABLE OF CONTENTS

                                                               PAGE(S)
                                                               -------

Report of Independent Accountants                                 F-1

Financial Statements:

  Balance Sheet as of September 30, 2003                          F-2

  Statement of Operations for the years ended
    September 30, 2003 and 2002                                   F-3

  Statement of Stockholders' Equity for the years
    ended September 30, 2003 and 2002                             F-4

  Statement of Cash Flows for the years ended
    September 30, 2003 and 2002                                   F-5

Notes to Financial Statements                                     F-6


<PAGE>


                        REPORT OF INDEPENDENT ACCOUNTANTS
                        ---------------------------------



To the Board of Directors and Stockholders of
HealthRenu Medical, Inc.


We  have audited the accompanying balance sheet of HealthRenu Medical, Inc. (the
"Company")  as  of September 30, 2003, and the related statements of operations,
stockholders'  equity  and cash flows for the years ended September 30, 2003 and
2002.  These  financial  statements  are  the  responsibility  of  the Company's
management.  Our  responsibility  is  to  express  an opinion on these financial
statements  based  on  our  audits.

We conducted our audits in accordance with auditing standards generally accepted
in  the  United  States  of  America.  Those  standards require that we plan and
perform  the  audits  to obtain reasonable assurance about whether the financial
statements are free of material misstatement.  An audit includes examining, on a
test  basis,  evidence  supporting  the amounts and disclosures in the financial
statements.  An audit also includes assessing the accounting principles used and
significant  estimates  made  by  management,  as well as evaluating the overall
financial  statement  presentation.  We  believe  that  our  audits  provide  a
reasonable  basis  for  our  opinion.

In  our  opinion,  the financial statements referred to above present fairly, in
all  material respects, the financial position of HealthRenu Medical, Inc. as of
September 30, 2003, and the results of its operations and its cash flows for the
years ended September 30, 2003 and 2002 in conformity with accounting principles
generally  accepted  in  the  United  States  of  America.




                                        /s/  Ham,  Langston  &  Brezina,  L.L.P.


Houston, Texas
December 15, 2003


                                       F-1

<PAGE>

<TABLE>
<CAPTION>

                            HEALTHRENU MEDICAL, INC.
                                  BALANCE SHEET
                               SEPTEMBER 30, 2003




ASSETS
------
<S>                                                       <C>
Current assets:
  Cash and cash equivalents                               $    17,684
  Inventories                                                  46,903
  Employee receivable                                           5,771
  Other current assets                                          5,000
                                                          ------------

    Total current assets                                       75,358

Property and equipment, net                                    56,903
                                                          ------------

      Total assets                                        $   132,261
                                                          ============


LIABILITIES AND STOCKHOLDERS' EQUITY
------------------------------------

Current liabilities:
  Accounts payable                                        $    78,004
  Accounts payable-stockholder                                  3,235
  Sales tax payable                                               600
  Notes payable to stockholders                                16,403
                                                          ------------

    Total current liabilities                                  98,242
                                                          ------------

Commitments and contingencies

Stockholders' equity:
  Convertible preferred stock, Series 2000A, $0.001 par
    value; 1,500,000 shares authorized, 1,763 shares
    issued and outstanding at September 30, 2003                    2
  Common stock, $.001 par value; 50,000,000 shares
    authorized, 15,506,962 shares issued and outstanding
    at September 30, 2003                                      15,507
  Additional paid-in capital                                  674,830
  Unissued common stock                                       698,602
  Stock subscription receivable                               (31,000)
  Accumulated deficit                                      (1,323,922)
                                                          ------------

      Total stockholders' equity                               34,019
                                                          ------------

        Total liabilities and stockholders' equity        $   132,261
                                                          ============


</TABLE>



                 See accompanying notes to financial statements.
                                       F-2

<PAGE>




<TABLE>
<CAPTION>


                            HEALTHRENU MEDICAL, INC.
                            STATEMENT OF OPERATIONS
                FOR THE YEARS ENDED SEPTEMBER 30, 2003 AND 2002



                                               YEAR ENDED SEPTEMBER 30,
                                              -------------------------
                                                  2003         2002
                                              ------------  -----------
<S>                                           <C>           <C>
Sales                                         $    26,281   $   78,502

Cost of sales                                      28,055       60,629
                                              ------------  -----------

    Gross profit (loss)                            (1,774)      17,873

General and administrative expenses               444,910      110,258

Cost of recapitalization                          561,982            -
                                              ------------  -----------

    Loss from operations                       (1,008,666)     (92,385)

Interest expense                                     (698)      (3,465)
                                              ------------  -----------

    Net loss                                  $(1,009,364)  $  (95,850)
                                              ============  ===========


Weighted average shares outstanding             9,567,894    8,891,974
                                              ============  ===========

Basic and diluted net loss per common share   $     (0.11)  $    (0.01)
                                              ============  ===========


</TABLE>


                 See accompanying notes to financial statements.
                                       F-3

<PAGE>

<TABLE>
<CAPTION>

                                                    HEALTHRENU MEDICAL, INC.
                                              STATEMENT OF STOCKHOLDERS' EQUITY
                                      FOR THE YEARS ENDED SEPTEMBER 30, 2003 AND 2002



                                                                       ADDITIONAL    COMMON       STOCK
                               PREFERRED STOCK     COMMON STOCK         PAID-IN       STOCK    SUBSCRIPTION   ACCUMULATED
                               SHARES    AMOUNT    SHARES     AMOUNT    CAPITAL     UNISSUED    RECEIVABLE     DEFICIT     TOTAL
                             ---------  -------  ----------  -------  ----------  -----------  ------------  ------------  --------
<S>                                     <C>      <C>         <C>      <C>         <C>          <C>           <C>
Balance at September 30, 2001      -    $     -   8,877,807  $ 8,878  $ 220,839   $        -   $         -   $  (218,708) $ 11,009

Common stock issued for cash       -          -      17,000       17     16,983            -             -             -    17,000

Cash received for common stock
  not yet issued                   -          -           -        -          -      127,600             -             -   127,600

Rent contributed by a stock-
  holder                           -          -           -        -      3,000            -             -             -     3,000

Net loss                           -          -           -        -          -            -             -       (95,850)  (95,850)
                             ---------  -------  ----------  -------  ----------  -----------  ------------  ------------  --------

Balance at September 30, 2002      -          -   8,894,807    8,895    240,822      127,600             -      (314,558)   62,759

Common stock issued for cash       -          -   2,317,392    2,318    197,682            -       (31,000)            -   169,000

Common stock issued for
  liabilities                      -          -      50,000       50     49,950            -             -             -    50,000

Effect of Exchange Agreement    1,763         2      59,263       59   (379,363)     379,302             -             -         -

Common stock issued for ser-
  vices                            -          -   4,024,250    4,024    399,300            -             -             -   403,324

Common stock issued for em-
  ployee compensation              -          -      36,000       36     35,964            -             -             -    36,000

Issuance of common stock for
  committed stock                  -          -     125,250      125    127,475     (127,600)            -             -         -

Shares issuable for consult-
  ing services                     -          -           -        -          -      274,300             -             -   274,300

Shares issuable for employee
  compensation                     -          -           -        -          -       45,000             -             -    45,000

Rent contributed by stock-
  holder                           -          -           -        -      3,000            -             -             -     3,000

Net loss                           -          -           -        -          -            -             -  (1,009,364) (1,009,364)
                             ---------  -------  ----------  -------  ----------  -----------  ------------  ------------  --------

Balance at September 30, 2003   1,763   $     2  15,506,962  $15,507  $ 674,830   $  698,602   $   (31,000) $(1,323,922)  $ 34,019
                             =========  =======  ==========  =======  ==========  ===========  ============  ============  ========

</TABLE>


                 See accompanying notes to financial statements.
                                       F-4

<PAGE>

<TABLE>
<CAPTION>

                            HEALTHRENU MEDICAL, INC.
                            STATEMENT OF CASH FLOWS
                FOR THE YEARS ENDED SEPTEMBER 30, 2003 AND 2002


                                                       YEAR  ENDED  SEPTEMBER  30,
                                                      ---------------------------
                                                           2003         2002
                                                       ------------  ----------
<S>                                                    <C>           <C>
Cash flows from operating activities:
  Net loss                                             $(1,009,364)  $ (95,850)
  Adjustments to reconcile net loss to net cash used
    in operating activities:
    Depreciation                                             4,905       3,330
    Rent expense contributed by stockholder                  3,000       3,000
    Cost of recapitalization-net liabilities assumed        24,482           -
    Cost of recapitalization-stock-based compensation      487,500           -
    Stock-based compensation for services                  190,124           -
    Stock-based employee compensation                       81,000           -
    Changes in operating assets and liabilities:
      Accounts receivable                                   16,276     (14,672)
      Employee receivable                                   (5,771)          -
      Other current assets                                  (5,000)          -
      Inventories                                            2,771     (18,906)
      Accounts payable                                      68,335      16,099
      Sales tax payable                                        477        (567)
                                                       ------------  ----------

        Net cash used in operating activities             (141,265)   (107,566)
                                                       ------------  ----------

Cash flows from investing activities:
  Purchase of fixed assets                                 (13,179)    (10,616)
                                                       ------------  ----------

        Net cash used in investing activities              (13,179)    (10,616)
                                                       ------------  ----------

Cash flows form financing activities:
  Decrease in book overdraft                                     -     (11,624)
  Payments on notes payable                                (10,000)     (1,666)
  Proceeds from issuance of common stock                   169,000      17,000
  Proceeds from common stock not yet issued                      -     127,600
                                                       ------------  ----------

        Net cash provided by financing activities          159,000     131,310
                                                       ------------  ----------

Increase in cash and cash equivalents                        4,556      13,128

Cash and cash equivalents, beginning of year                13,128           -
                                                       ------------  ----------

Cash and cash equivalents, end of year                 $    17,684   $  13,128
                                                       ============  ==========


Supplemental disclosure of cash flow information:
  Cash paid for interest                               $       698   $   3,465
                                                       ============  ==========

  Cash paid for income taxes                           $         -   $       -
                                                       ============  ==========

  Non-cash investing and financing activities:
    Issuance of common stock as payment of liability   $    50,000   $       -
                                                       ============  ==========

</TABLE>




                 See accompanying notes to financial statements
                                       F-5

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                          NOTES TO FINANCIAL STATEMENTS


1.     BACKGROUND  AND  SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
       ---------------------------------------------------------------

BACKGROUND
----------

HealthRenu Medical, Inc. (the "Company"), a Nevada corporation, is headquartered
in  Friendswood,  Texas,  with operations in Guntersville, Alabama.  The Company
produces and distributes various skin care products primarily to the home health
care  and  other  medical  markets  throughout  the  United  States.

The  Company  was  originally  incorporated  in Delaware as Health Renu, Inc. in
1997.  In  September  2003,  upon  completion  of  a  recapitalization  through
acquisition  of a non-operating public shell, the name was changed to HealthRenu
Medical,  Inc.  The  public shell had no significant assets or operations at the
date  of  acquisition.  The  Company assumed all liabilities of the public shell
that  remained  on  the  date  of  the  acquisition.  The  historical  financial
statements  presented  herein  are  those  of  HealthRenu Medical, Inc., and its
predecessor,  Health  Renu,  Inc.

The  non-operating  public shell used to recapitalize the Company was originally
incorporated  in  Colorado  as  American  Merger  Control,  Inc and subsequently
adopted  name changes to Ultratech Knowledge  Systems, Inc., and AGTsports, Inc.
In  2003, the Company was reincorporated in the state of Nevada and subsequently
changed  its  name  to  its  current  name,  HealthRenu  Medical,  Inc.

Following  is  a  summary  of  the  Company's  significant  accounting policies.

USE  OF  ESTIMATES
------------------

The preparation of financial statements in conformity with accounting principles
generally  accepted  in the United States of America requires management to make
estimates  and assumptions that affect reported amounts and related disclosures.
Actual  results  could  differ  from  those  estimates.

REVENUE  RECOGNITION
--------------------

Revenue  is  recognized  when  products  are  shipped.

CONCENTRATIONS  OF  CREDIT  RISK
--------------------------------

Financial instruments which subject the Company to concentrations of credit risk
include  cash  and  cash  equivalents  and  accounts  receivable.

The  Company  maintains  its  cash  in  well-known  banks  selected  based  upon
management's  assessment  of  the  banks'  financial  stability.  Balances  may
periodically  exceed  the  $100,000 federal depository insurance limit; however,
the  Company  has  not  experienced  any  losses  on  deposits.

Accounts  receivable generally arise from sales of various skin care products to
the  home  health  care  and other medical markets throughout the United States.
Collateral  is  generally  not  required  for  credit  granted.

CASH  EQUIVALENTS
-----------------

For  purposes  of  reporting  cash  flows,  the Company considers all short-term
investments  with  an  original  maturity  of  three  months  or less to be cash
equivalents.



                                    Continued
                                       F-6

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED


1.     BACKGROUND  AND  SUMMARY  OF  SIGNIFICANT  ACCOUNTING POLICIES, CONTINUED
       -------------------------------------------------------------------------

PROPERTY  AND  EQUIPMENT
------------------------

Property and equipment are recorded at cost.  Depreciation is provided using the
straight-line  method over the estimated useful lives of the assets, which range
from  three  to  twenty-five  years.  Expenditures  for  major  renewals  and
betterments  that  extend  the  original  estimated economic useful lives of the
applicable  assets  are  capitalized.  Expenditures  for  normal  repairs  and
maintenance  are  charged  to  expense  as  incurred.  The  cost  and  related
accumulated  depreciation  of  assets  sold or otherwise disposed of are removed
from  the  accounts,  and  any  gain  or  loss  is  included  in  operations.

INVENTORIES
-----------

Inventories consist of raw materials, work-in-process and finished goods and are
stated at the lower of cost or market.  Cost is computed using actual costs on a
first-in, first-out basis.

SHIPPING  AND  DELIVERY  COSTS
------------------------------

The  cost  of shipping and delivery are charged directly to cost of sales at the
time  of  shipment.

RESEARCH  AND  DEVELOPMENT
--------------------------

Research  and  development  activities are expensed as incurred, including costs
relating  to  patents  or  rights,  which  may  result  from  such expenditures.
Research and development expense for the years ended September 30, 2003 and 2002
was  $50,354  and  $1,090,  respectively.

INCOME  TAXES
-------------

The  Company  uses  the  liability method of accounting for income taxes.  Under
this  method, deferred income taxes are recorded to reflect the tax consequences
on  future  years  of  temporary differences between the tax basis of assets and
liabilities  and  their  financial  amounts at year-end.  The Company provides a
valuation allowance to reduce deferred tax assets to their net realizable value.

LOSS  PER  SHARE
----------------

Basic  and  diluted  loss  per  share  is  computed on the basis of the weighted
average number of shares of common stock outstanding during each period.  Common
equivalent  shares  from common stock options and warrants are excluded from the
computation  as  their  effect  would  dilute the loss per share for all periods
presented.

IMPAIRMENT  OF  LONG-LIVED  ASSETS
----------------------------------

In  the event that facts and circumstances indicate that the carrying value of a
long-lived  asset,  including  associated  intangibles,  may  be  impaired,  an
evaluation  of  recoverability  is  performed  by comparing the estimated future
undiscounted  cash flows associated with the asset or the asset's estimated fair
value  to  the  asset's  carrying  amount to determine if a write-down to market
value  or  discounted  cash  flow  is  required.



                                    Continued
                                       F-7

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED


1.     BACKGROUND  AND  SUMMARY  OF  SIGNIFICANT  ACCOUNTING POLICIES, CONTINUED
       -------------------------------------------------------------------------

FAIR  VALUE  OF  FINANCIAL  INSTRUMENTS
---------------------------------------

The Company includes fair value information in the notes to financial statements
when  the  fair  value  of  its financial instruments is different from the book
value.  When the book value approximates fair value, no additional disclosure is
made.

COMPREHENSIVE  INCOME
---------------------

Comprehensive  income  includes  such  items  as  unrealized  gains or losses on
certain  investment  securities  and  certain  foreign  currency  translation
adjustments.  The  Company's financial statements include none of the additional
elements  that  affect  comprehensive income.  Accordingly, comprehensive income
(loss)  and  net  income  (loss)  are  identical.

STOCK-BASED  COMPENSATION
-------------------------

Stock-based  compensation  is  accounted  for  using  the intrinsic value method
prescribed  in  Accounting  Principles Board Opinion ("APB") No. 25, "Accounting
for  Stock  Issued  to  Employees",  rather  than applying the fair value method
prescribed  in  SFAS  No.  123,  "Accounting  for  Stock-Based  Compensation".

RECENT  ACCOUNTING  PRONOUNCEMENTS
----------------------------------

In July 2001, the Financial Accounting Standards Board ("FASB") issued Statement
of Financial Accounting Standards ("SFAS") No. 141, Business Combinations, which
requires all business combinations initiated after June 30, 2001 to be accounted
for  using the purchase method.  In addition, SFAS No. 141 further clarifies the
criteria  to  recognize  intangible  assets  separately  from  goodwill.  The
implementation  of  SFAS No. 141 did not impact the Company's financial position
or  results  of  operations  because  the  Company did not complete any business
combinations,  other  than  a  recapitalization  (See  Note  2),  or  record any
significant  intangibles  during  the  years  ended  September 30, 2003 or 2002.

In June 2001, the Financial Accounting Standards Board ("FASB") issued Financial
Accounting  Standard  ("SFAS")  No. 142, "Goodwill and Other Intangible Assets".
SFAS  No. 142 eliminates the amortization of goodwill and requires that goodwill
be reviewed annually for impairment.  SFAS No. 142 also requires that the useful
lives of previously recognized intangible assets be reassessed and the remaining
amortization  periods  be  adjusted  accordingly.  SFAS No. 142 is effective for
fiscal  years  beginning  after  December  15, 2001 and affects all goodwill and
other  intangible  assets  recorded on the Company's balance sheet at that date,
regardless  of  when  the assets were initially recorded.  The implementation of
SFAS  No.  142  did  not  have  a  material  impact  on the Company's results of
operations  or  financial  position.

In  June  2001,  the  FASB issued SFAS No. 143, "Accounting for Asset Retirement
Obligations".  SFAS  No.  143 addresses accounting and reporting for obligations
associated  with the retirement of tangible long-lived assets and the associated
asset  retirement costs.  This statement is effective for fiscal years beginning
after June 15, 2002.  The implementation of SFAS No. 143 did not have a material
impact  on  the  Company's  results  of  operation  or  financial  position.




                                    Continued
                                       F-8

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED


1.     BACKGROUND  AND  SUMMARY  OF  SIGNIFICANT  ACCOUNTING POLICIES, CONTINUED
       -------------------------------------------------------------------------

RECENT  ACCOUNTING  PRONOUNCEMENTS,  CONTINUED
----------------------------------------------

In  July  2001,  the  FASB  issued  SFAS  No.  144,  "Impairment  or Disposal of
Long-Lived Assets", which is effective for fiscal years beginning after December
15,  2001.  The  provisions  of this statement provide a single accounting model
for impairment of long-lived assets.  The implementation of SFAS No. 144 did not
have  a  material  impact  on  the  Company's  results of operation or financial
position.

In  April  2002, the FASB issued SFAS No. 145, Rescission of FASB Statements No.
4,  44  and  64,  Amendment of FASB Statement No. 13, and Technical Corrections.
SFAS  No.  145  requires  that  gains  and losses from extinguishment of debt be
classified  as  extraordinary items only if they meet the criteria in Accounting
Principles  Board Opinion No. 30 ("Opinion No. 30").  Applying the provisions of
Opinion  No.  30  will  distinguish  transactions  that  are part of an entity's
recurring  operations  from  those  that are unusual and infrequent and meet the
criteria for classification as an extraordinary item.  SFAS No. 145, which is to
be  applied  to  all  periods  presented, is effective for the Company beginning
January  1,  2003.  The  implementation  of SFAS No. 145 did not have a material
impact  on  the  Company's  results  of  operations  or  financial  position.

In July 2002, the FASB issued SFAS No. 146, Accounting for Costs Associated with
Exit  or  Disposal  Activities.  SFAS No. 146 addresses accounting and reporting
for  costs  associated with exit or disposal activities, such as restructurings,
involuntarily  terminating  employees,  and  consolidating  facilities initiated
after  December  31,  2002.  SFAS  No. 146, which requires that costs related to
exiting  an activity or to a restructuring not be recognized until the liability
is  incurred,  is  effective  for  the  Company beginning January 1, 2003 and is
applied on a prospective basis.  The implementation of SFAS No. 146 did not have
a  material impact on the Company's results of operations or financial position.

In  December  2002,  the  FASB  issued  SFAS No. 148, Accounting for Stock-Based
Compensation,  Transition  and  Disclosure.  SFAS  No.  148 provides alternative
methods  of  transition for a voluntary change to the fair value based method of
accounting  for stock-based employee compensation and requires fair value method
proforma  disclosures  to be displayed more prominently and in a tabular format.
Additionally,  SFAS  No.  148  requires similar disclosures in interim financial
statements.  The  Company  did  not  voluntarily  change to the fair value based
method  of  accounting  for stock-based employee compensation, but did adopt the
transition  and  disclosure  requirements  of SFAS No. 148 during the year ended
September  30,  2003.

In  April  2003,  the  FASB  issued  SFAS No. 149, Amendment of Statement 133 on
Derivative  Instruments  and Hedging Activities.  SFAS 149 is intended to result
in  more  consistent  reporting  of  contracts as either freestanding derivative
instruments  subject  to SFAS 133 in its entirety, or as hybrid instruments with
debt  host  contracts  and  embedded derivative features.  In addition, SFAS 149
clarifies the definition of a derivative by providing guidance on the meaning of
initial  net  investments  related  to  derivatives.  SFAS  149 is effective for
contracts  entered  into or modified after June 30, 2003.  The implementation of
SFAS  149 did not have any effect on the Company's financial position or results
of  operations.





                                    Continued
                                       F-9

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED


1.     BACKGROUND  AND  SUMMARY  OF  SIGNIFICANT  ACCOUNTING POLICIES, CONTINUED
       -------------------------------------------------------------------------

RECENT  ACCOUNTING  PRONOUNCEMENTS,  CONTINUED
----------------------------------------------

In  May  2003,  the  FASB  issued SFAS No. 150, Accounting for Certain Financial
Instruments  with  Characteristics  of  both  Liabilities  and  Equity. SFAS 150
establishes  standards  for  classifying  and  measuring  as liabilities certain
financial  instruments  that  embody  obligations  of  the  issuer  and  have
characteristics  of  both  liabilities  and  equity.  SFAS  150  represents  a
significant  change  in  practice  in  the  accounting for a number of financial
instruments,  including  mandatory  redeemable  equity  instruments  and certain
equity  derivatives that frequently are used in connection with share repurchase
programs.  SFAS  150  is  effective  for  all  financial  instruments created or
modified  after  May 31, 2003, and to other instruments as of September 1, 2003.
The  Company  adopted  SFAS  150  on June 1, 2003. This statement did not have a
material  impact  on  the Company's financial position or results of operations.

In  November  2002,  the  FASB  issued  FASB  Interpretation  No.  45, Guarantor
Accounting  and  Disclosure  Requirements  for  Guarantees,  Including  Indirect
Guarantees of Indebtedness of Others ("FIN 45").  FIN 45 requires a guarantor to
recognize,  at  the  inception of a guarantee, a liability for the fair value of
the  obligation  undertaken  in  issuing the guarantee.  FIN 45 also expands the
disclosures  required  to  be  made  by  a guarantor about its obligations under
certain  guarantees  that  it  has  issued.  Initial recognition and measurement
provisions  of FIN 45 are applicable on a prospective basis to guarantees issued
or  modified.  The  disclosure  requirements  are  effective  immediately.  The
adoption of FIN 45 did not impact the Company's financial position or results of
operations.

In  January  2003,  the FASB issued Interpretation 46, Consolidation of Variable
Interest  Entities  ("FIN  46").  FIN  46  requires  that companies that control
another  entity through interests other than voting interests should consolidate
the  controlled  entity.  FIN  46  applies to variable interest entities created
after January 31, 2003, and to variable interest entities in which an enterprise
obtains an interest in after that date.  The related disclosure requirements are
effective  immediately.  The  implementation  of  FIN 46 did not have a material
effect  on  the  Company's  financial  position  or  results  of  operations.


2.     RECAPITALIZATION
       ----------------

In  September  2003,  Health Renu, Inc. entered into an agreement whereby Health
Renu,  Inc.  agreed to exchange 100% of the issued and outstanding shares of its
common  stock  and  $50,000  for  approximately  99% or 15,447,699 shares of the
issued  and  outstanding common stock of AGTSports, Inc. (a non-operating public
shell  corporation).  The  agreement  represented  a  recapitalization of Health
Renu,  Inc.  with  accounting  treatment  similar  to  that  used  in  a reverse
acquisition,  except  that  no  goodwill  or  intangible  asset  is recorded.  A
recapitalization  is  characterized by the merger of a private operating company
into  a  non-operating  public  shell  corporation  with  nominal net assets and
typically  results  in  the  owners  and  managers of the private company having
effective  or  operating  control after the transaction.  The Company emerged as
the  surviving  financial  reporting  entity under the agreement, but AGTSports,
Inc.  (which changed its name to HealthRenu Medical, Inc.) remained as the legal
reporting  entity.




                                    Continued
                                      F-10

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED


3.     INVENTORIES
       -----------

Inventories  consist  of  the  following  at  September  30,  2003:

     Work-in-process                                                $   31,841
     Finished  goods                                                    15,062
                                                                    ----------

                                                                    $   46,903
                                                                    ==========

4.     PROPERTY  AND  EQUIPMENT
       ------------------------

Property  and  equipment  consisted  of  the  following  at  September 30, 2003:

       Furniture  and  fixtures                                     $    2,427
       Buildings  and  equipment                                        79,279

       Less:  accumulated  depreciation                               (24,803)
                                                                    ----------

         Property  and  equipment,  net                             $   56,903
                                                                    ==========


Depreciation  expense for the years ended September 30, 2003 and 2002 was $4,905
and  $3,330,  respectively.


5.     NOTES  PAYABLE  TO  STOCKHOLDERS
       --------------------------------

Notes  payable to stockholders consisted of the following at September 30, 2003:

Notes  payable  to  a  stockholder,  accruing  interest
  at  10%  to  27%,  principal  and  interest  due  on
  demand.  These  notes  are  not  collateralized.                  $    7,403

Note  payable  to  a  stockholder,  interest  due  monthly
  at  10%  per  year,  principal  due  on  January  15,  2003.
  This  note  is  not  collateralized.                                   8,000

Note  payable  to  a  stockholder,  accruing  interest  at
  10%,  principal  and  interest  due  on  June  1,  2004.
  This  note  is  not  collateralized.                                   1,000
                                                                    ----------

    Total  notes  payable  to  stockholders                         $   16,403
                                                                    ==========


6.     INCOME  TAXES
       -------------

The Company has incurred losses since its inception and, therefore, has not been
subject  to federal income taxes.  As of September 30, 2003, the Company had net
operating  loss  ("NOL")  carryforwards for income tax purposes of approximately
$1,333,372 which expire in various tax years through 2023.  Under the provisions
of  Section  382 of the Internal Revenue Code an ownership change in the Company
could  severely  limit  the Company's ability to utilize its NOL carryforward to
reduce future taxable income and related tax liabilities.  Additionally, because
United  States  tax  laws  limit  the time during which NOL carryforwards may be
applied  against  future  taxable income, the Company may be unable to take full
advantage of its NOL for federal income tax purposes should the Company generate
taxable  income.


                                    Continued
                                      F-11

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED
                                   __________


6.     INCOME  TAXES,  CONTINUED
       -------------------------

The  composition  of  deferred  tax  assets  and liabilities and the related tax
effects  at  September  30,  2003  are  as  follows:

  Deferred  tax  assets:
    Net  operating  losses                                          $  453,346
    Valuation  allowance                                              (453,346)
                                                                    ----------

      Net  deferred  tax  asset  (liability)                        $     -
                                                                    ===========


The  difference  between the income tax benefit in the accompanying statement of
operations  and  the amount that would result if the U.S. federal statutory rate
of  34%  were applied to pre-tax loss for the years ended September 30, 2003 and
2002  is  as  follows:
                                           2003                     2002
                                   --------------------     --------------------
                                    AMOUNT     PERCENT       AMOUNT     PERCENT
                                   --------     -------     --------     -------

  Benefit  for  income  tax  at
    federal  statutory  rate     $  343,184      34.0%     $   31,824      34.0%
  Non-deductible  expense               (42)        -              (4)        -
  Increase  in  valuation
    allowance                      (343,142)    (34.0)        (31,820)    (34.0)
                                  ----------    -------     ----------   -------

                                 $        -         -%     $        -         -%
                                  ==========    =======     ==========   =======


7.     COMMITMENTS  AND  CONTINGENCIES
       -------------------------------

LEASES
------

The  Company  leases  office  space  and facilities under operating leases which
expire  at  various  dates  through  2012.  These  leases  require  monthly rent
payments.  The  leases  do  not  generally include renewal options; however, the
Company  intends  to  renew  its leases in the normal course of business. Future
minimum lease payments on leases having initial or noncancellable lease terms in
excess  of  one  year  at  September  30,  2003  are  as  follows:

                             OPERATING
                               LEASES
                              -------

       2004                $   17,300
       2005                     3,000
       2006                     3,000
       2007                     3,000
       2008                     3,000
       Thereafter              10,750
                           ----------

       Total  payments     $   40,050
                           ==========


Total  rent  expense  for the years ended September 30, 2003 and 2002 was $7,190
and  $5,250,  respectively.




                                    Continued
                                      F-12

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED


7.     COMMITMENTS  AND  CONTINGENCIES,  CONTINUED
       -------------------------------------------

CONSULTING  AGREEMENT
---------------------

In  August  2001  the  Company  entered  into  a  consulting  agreement  with an
individual  whereby  he  is  to  provide  various marketing and other consulting
services  to the Company for a fee of $3,500 per month and 653,664 shares of the
Company's  common  stock.  The shares were to be earned and issued only upon the
successful  completion  of  the Company becoming a publicly traded company.  The
agreement  was  subsequently canceled and a new agreement was entered into.  The
new  agreement, effective October 1, 2003, has a term of five years and provides
for  $9,000 of compensation per month.  In addition to monthly compensation, the
consultant will receive 4% of each closed transaction involving fund raising and
completed  mergers  and acquisitions.  Included in accounts payable at September
30,  2003  is  $17,500  owed  to  this  individual.

EMPLOYMENT  AGREEMENT
---------------------

In  September  2003,  the  Company entered into an employment agreement with its
chief  executive  officer.  The  one-year  employment  agreement provides for an
annual  salary  as  well  as a one time issuance of 450,000 shares of restricted
stock  upon  signing  of the agreement and 37,500 shares of restricted stock per
month  as  part  of  the  base salary compensation. As of September 30, 2003 the
value  of  the  shares  of  approximately  $45,000 has been included in unissued
stock. In addition, the agreement provides for six (6) months of compensation in
the  event  of non-renewal of the contract by the Company for reasons other than
cause  and  reimbursement of non-elective medical expenses incurred by the Chief
Executive  Officer.


8.     PREFERRED  STOCK
       ----------------

Prior  to  the  recapitalization,  the Company was authorized to issue 5,000,000
shares  of  convertible  preferred  stock,  $.001  par  value.  The  convertible
preferred  stockholders  had  priority  rights  to  dividend  distributions  and
liquidation  distributions  over  the  common  stockholders  in  the  event  of
dissolution.  As  of  September 30, 2002 there were no shares of preferred stock
issued  and  outstanding.

As  a  result  of the recapitalization, the new articles of incorporation of the
Company  stipulate  that  the Company is authorized to issue 5,000,000 shares of
preferred stock, $.001 par value.  Of the 5,000,000 authorized shares, 1,500,000
shares  of  preferred  stock  have  been  designated  Series  2000A  Convertible
Preferred  stock  (Series 2000A Preferred).  The shareholders of these preferred
shares  are  entitled  to  a  preference  in liquidation of ten cents per share.
These  preferred  shareholders  also  receive dividends on a pro-rata basis with
common  stockholders  at  the  election of the board of directors.  No dividends
have  been  declared as of September 30, 2003.  Each share is convertible at the
option of the shareholder to one share of common stock.  In addition, the shares
will  automatically  convert  to  common  shares  upon  the  closing  of  a firm
commitment  underwritten  public  offering  with  net  proceeds  in  excess  of
$2,000,000  or  a  vote  of  two-thirds  of  the  preferred shareholders.  As of
September  30,  2003,  there  are  1,763  shares of Series 2000A Preferred stock
outstanding.  No  other  preferred  stock  is outstanding at September 30, 2003.



                                    Continued
                                      F-13

<PAGE>

                            HEALTHRENU MEDICAL, INC.
                    NOTES TO FINANCIAL STATEMENTS, CONTINUED



9.     RELATED  PARTY  TRANSACTIONS
       ----------------------------

One  of  the  Company's offices is located in the home of a major stockholder of
the  Company.  The  stockholder has not charged the Company rent for this space.
The  fair  market value of the rent has been estimated at approximately $250 per
month.  Therefore,  included  in  the  accompanying  statement  of operations is
$3,000  of rent expense for each of the years ended September 30, 2003 and 2002.

During  the  years  ended  September 30, 2003 and 2002, the Company issued stock
with a value of approximately $46,000 and $0, respectively to a company owned by
the  President  of  the  Company  for  research  and  development  services.

Effective  April  30,  2002  the Company entered into a lease agreement with the
father  of  the  chief executive officer and major stockholder of the Company to
lease  33  acres of land in Texas to be used in the production of raw materials.
The  lease  payments are $250 per month for ten years.  As of September 30, 2003
no  lease  payments were made and included in accounts payable is $4,250 related
to  this  lease.




10.     SUBSEQUENT  EVENTS
        ------------------

Effective  November  1,  2003,  the Company entered into an employment agreement
with  its  President.  The  one-year employment agreement provides for an annual
salary  as well as six months of compensation in the event of non-renewal of the
contract  by  the  Company  for  reasons  other  than cause.  The agreement also
stipulates  that  the  Company will reimburse the President for all non-elective
medical  expenses  incurred  out  of  pocket.

On  November  25, 2003, the Company entered into a one-year consulting agreement
with  an  individual.  As  compensation  for these services, the consultant will
receive  25,000  shares  of  the  Company's  common  stock.

In  October,  November  and December 2003, 3,779,302 shares of common stock were
issued  for  common  stock  committed  at  September  30,  2003.





                                      F-14

<PAGE>


ITEM 8.  CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
         FINANCIAL DISCLOSURE

For  the  fiscal  year  ended  September 30, 2002 and 2001, the firm of Brimmer,
Burke  &  Keelan,  LLP  ("Brimmer")  served as the Company's auditors. Effective
October  8,  2003,  the Board of Directors of the Company approved the change of
accountants.  On  that  date,  management  of  the Company dismissed Brimmer and
engaged  Ham,  Langston  &  Brezina,  LLP  of  Houston,  Texas  as its principal
independent  public  accountant to audit its financial statements for the fiscal
years  ended  September  30,  2003  and  September  30,  2002.

Ham,  Langston  &  Brezina,  LLP  succeeded  Brimmer.  Brimmer's  report  on the
financial  statements of the Company (formerly AGTSports, Inc.) from the date of
its  incorporation  on  January 6, 1986 through September 30, 2002 and any later
interim  period  up  to  and  including  the  date the relationship with Brimmer
ceased, did not contain any adverse opinion or disclaimer of opinion and was not
qualified  or  modified as to uncertainty, audit scope or accounting principles.

                                      -14-
<PAGE>

In  connection  with  the  audit  of  the Company's two most recent fiscal years
ending  September  30,  2002 and any later interim period, including the interim
period  up to and including the date the relationship with Brimmer ceased, there
have  been no disagreements with Brimmer on any matters of accounting principles
or  practices,  financial  statement  disclosure of auditing scope or procedure,
which disagreement(s), if not resolved to the satisfaction of Brimmer would have
caused Brimmer to make reference to the subject matter of the disagreement(s) in
connection  with  its  report  on  the  Company' financial statements. Since the
Company's incorporation on January 6, 1986, there have been no reportable events
as  defined  in  Item  301(a)(1)(v)  of  Regulation  S-K.

The  Company  authorized  Brimmer  to  respond fully to any inquiries of any new
auditors  hired  by  the  Company  relating to their engagement as the Company's
independent accountant. The Company requested that Brimmer review the disclosure
and  Brimmer  was  given  an  opportunity  to  furnish the Company with a letter
addressed to the Commission containing any new information, clarification of the
Company's  expression  of  its  views, or the respect in which it does not agree
with  the  statements  made  by  the  Company in the Report on Form 8-K filed on
October  30,  2003.  Such  letter  was  filed  as  an  exhibit to such Form 8-K.

The  Company  had  not  previously  consulted  with Ham, Langston & Brezina, LLP
regarding  either  (i)  the  application of accounting principles to a specified
transaction,  either  completed  or  proposed; or (ii) the type of audit opinion
that  might  be  rendered  on  the  Company's financial statements; or (iii) any
matter  that was either the subject matter of a disagreement (as defined in Item
304(a)(1)(iv)  of  Regulation  S-K  and  the  related  instructions) between the
Company  and  Brimmer,  the  Company's previous independent accountant, as there
were  no  such  disagreements  or  an other reportable event (as defined in Item
304(a)(1)(v)  of  Regulation S-K) from the Company's incorporation on January 6,
1986  through  December  31,  2002  and  any later interim period, including the
interim  period  up  to  and  including  the  date the relationship with Brimmer
ceased.  Neither  had the Company received any written or oral advice concluding
there  was  an  important  factor  to be considered by the Company in reaching a
decision  as  to  an  accounting,  auditing,  or financial reporting issue. Ham,
Langston  &  Brezina,  LLP  reviewed  the  Company's disclosure required by Item
304(a)  before  it was filed with the Commission and was provided an opportunity
to furnish the Company with a letter addresssed to the Commission containing any
new  information, clarification of the Company's expression of its views, or the
respects  in  which  it did not agree with the statements made by the Company in
response  to  Item 304(a). Ham, Langston & Brezina, LLP did not furnish a letter
to  the  Commission.

ITEM 8A.  CONTROLS AND PROCEDURES

(a)  Evaluation  of  disclosure  controls  and  procedures.  Our chief executive
     officer and principal financial officer, after evaluating the effectiveness
     of  the  Company's  "disclosure controls and procedures" (as defined in the
     Securities  Exchange  Act  of 1934 Rules 13a-15(e) and 15d-15(e)) as of the
     end  of  the  period covered by this annual report (the "Evaluation Date"),
     have  concluded that as of the Evaluation Date, our disclosure controls and
     procedures  were  adequate and designed to ensure that material information
     relating  to  us  and  our consolidated subsidiaries would be made known to
     them  by  others  within  those  entities.

                                      -15-
<PAGE>

(b)  Changes  in  internal  control  over  financial  reporting.  There  were no
     significant changes in our internal control over financial reporting during
     the fourth fiscal quarter that materially affected, or is reasonably likely
     to  materially  affect,  our  internal  control  over  financial reporting.


                                    PART III

ITEM 9.  DIRECTORS, EXECUTIVE OFFICERS, PROMOTERS AND CONTROL PERSONS
         COMPLIANCE WITH SECTION 16(A) OF THE EXCHANGE ACT

DIRECTORS AND OFFICERS

The Directors and Officers of the Company are as follows:

                                                               Served as a
 Name                   Age      Position                     Director Since:
 ----                   ---      --------                     ---------------
Randy Mullins           50     Chief Executive Officer         August 2003
                               and Chairman

Darrell Good            48     Director and President          September 2003

Randy Mullins, CPA, has served as our CEO and Chairman of the Board of Directors
since  August  2003.  Prior  to joining the Company, Mr. Mullins had been a self
employed CPA since June 2001. From May 2000 to June 2001, Mr. Mullins worked for
Innovative  Physician  Solutions as a Clinic Manager and Analyst. Prior to that,
Mr.  Mullins  had  been  a self-employed CPA since January 1997. Mr. Mullins has
over  twenty  years of business and financial management experience working with
private  and  public  companies.  Mr.  Mullins  received  a  Bachelors degree in
accounting  from  Texas  Tech  University.  Mr. Mullins is a licensed CPA in the
State  of  Texas  and  has  been a member of the American Institute of Certified
Public  Accountants,  the  Texas  Society  of  Certified  Public  Accountants  -
Panhandle  Chapter,  the  Healthcare  Financial  Management Association, and the
Medical  Group  Management  Association.

Darrell Good has served as our President and as a Director since September 2003.
Mr.  Good  founded  Health  Renu,  Inc.,  the  Company's wholly-owned subsidiary
("Health  Renu")  in 1996. Mr. Good currently serves as President of Health Renu
and  has  served as such since 1997. With the help of a pharmaceutical firm, Mr.
Good  developed the formulas for Health Renu's products that are currently being
used  in  the medical field for treatment of various types of skin disorders and
non-healing  wounds.  The  main focus of these products is in geriatric skin and
wound  care  and treatment of diabetic ulcers. Darrell Good has served full-time
for  Health  Renu  since  September  of 1997. Mr. Good attended Tennessee Temple
University.  Mr. Good was involved with civil engineering, highway construction,
land  development,  home  construction  and  offshore  drilling  from 1980-1997.

All  Directors  of the Company will hold office until the next annual meeting of
the  shareholders,  and  until their successors have been elected and qualified.
Officers of the Company are elected by the Board of Directors and hold office at
the  pleasure  of  the  Board.

                                      -16-
<PAGE>

SECTION 16 (A) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE

Section  16(a)  of the Securities Exchange Act of 1934, as amended, requires the
Company's  directors,  executive officers and persons who own more than 10% of a
class of the Company's equity securities which are registered under the Exchange
Act  to  file  with  the  Securities  and Exchange Commission initial reports of
ownership  and  reports  of  changes of ownership of such registered securities.
Such  executive  officers,  directors and greater than 10% beneficial owners are
required  by  Commission  regulation  to  furnish the Company with copies of all
Section  16(a)  forms  filed  by  such  reporting  persons.

To  the  Company's  knowledge,  based  solely  on a review of the copies of such
reports  furnished  to  the Company and on representations that no other reports
were  required,  no  person required to file such a report failed to file during
fiscal  2003.  Based  on  stockholder  filings  with  the SEC, Randy Mullins and
Darrell  Good  are  subject  to  Section  16(a)  filing  requirements.

CODE OF ETHICS

The  Company  has  not  adopted  a  code of ethics that applies to the Company's
principal  executive  officer,  principal  financial  officer  or controller, or
persons  performing  similar functions. The Company has not had adequate time to
adopt  such  a  code of ethics as the Company had a change in control during the
fourth  quarter  of  the fiscal year ended September 30, 2003 as reported on the
Form  8-K  filed  on  September  29,  2003.

ITEM 10. EXECUTIVE COMPENSATION

Compensation  paid  to  Officers  and  Directors  is  set  forth  in the Summary
Compensation  Table  below. The Company may reimburse its Officers and Directors
for  any and all out-of-pocket expenses incurred relating to the business of the
Company.

<TABLE>
<CAPTION>


                     SUMMARY COMPENSATION TABLE

                                                        LONG-TERM COMPENSATION
                                                   ----------------------------------
                            ANNUAL COMPENSATION          AWARDS       PAYOUTS
                          -----------------------  ------------------ -------
                                                           SECURITIES
                                                            UNDERLY-
                                           OTHER     RE-      ING               ALL
                                           ANNUAL  STRICTED OPTIONS/           OTHER
NAME AND PRINCIPAL                         COMPEN-  STOCK     SARs     LTIP    COMPEN-
    POSITION        YEAR  SALARY   BONUS   SATION  AWARD(S) (NUMBER)  PAYOUTS  SATION
------------------  ----  -------  -----   ------  -------- --------  -------  ------
<S>                                      <C>                          <C>  <C>  <C>
Randy Mullins,      2003  $ 3,000     --      --   450,000(1)   --        --       --
CEO and Director

Darrell Good,       2003  $59,575     --      --       --       --        --       --
President and
Director

Cory Coppage,       2003  $38,241     --      --       --       --        --       --
Former CEO and      2002  $60,000     --      --    22,500      --        --       --
Director            2001  $60,000     --      --       --       --        --       --
</TABLE>

    (1)     These shares were issued in December 2003.

EMPLOYMENT AGREEMENTS

On August 1, 2003 AGTsports, Inc entered into an employment agreement with Randy
Mullins  as  Chief  Executive Officer for a term of three (3) years. Pursuant to
that  agreement,  which has been amended, as discussed below, Mr. Mullins was to
receive  an  annual  salary  of  $72,000,  and a one-time stock bonus of 500,000
Series  2003A  preferred stock of the Company. During September 2003, HealthRenu
Medical,  Inc.  (formerly  AGTsports,  Inc.)  amended  the  previous  employment
agreement with Mr. Mullins. Pursuant to the amended agreement, Mr. Mullins is to
serve as the Company's Chief Executive Officer for a term of twelve (12) months,
to  receive  an  annual  salary  of  $72,000, and as additional consideration to
receive 1) 450,000 shares of the Company's Common Stock for joining the Company;
and 2) 37,500 shares of the Company's Common Stock per month for each full month
of  service to a maximum of 450,000 shares, provided that the Board of Directors
of  the  Company  has  not  previously  exercised  its discretion to cancel such
additional  consideration.  The agreement is renewable upon the mutual agreement
of  the  parties.  If the Company fails to renew the contract, for reasons other
than  cause,  then Mr. Mullins is entitled to six (6) months compensation at the
rate  in  effect  at  the  time  of  the  non  renewal.

On  November  1,  2003  the  Company  entered  into an Employment Agreement with
Darrell Good as President and as a Director of the Company for a term of one (1)
year.  Pursuant  to  the agreement Mr. Good is to receive a salary of $7,000 per
month.  The  agreement is renewable upon the mutual agreement of the parties. If
the  Company fails to renew the contract, for reasons other than cause, then Mr.
Good  is  entitled  to  six (6) months compensation at the rate in effect at the
time  of  the  non  renewal.

                                      -17-
<PAGE>

ITEM 11. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND
         RELATED STOCKHOLDER MATTERS

The  following table sets forth information as of January 13, 2004, with respect
to the beneficial ownership of the common stock by (i) each director and officer
of the Company, (ii) all directors and officers as a group and (iii) each person
known  by  the  Company  to  own  beneficially  5%  or more of the common stock:

    Name and Address of                    Shares Owned            % of Class
    Beneficial Owner                      Beneficially(1)             Owned
    -------------------                   ---------------           ---------
    Randy Mullins                            800,000(2)                4.1%
    16107 Affirmed Way
    Friendswood, Texas 77546

    Darrell Good                           8,115,000(3)               41.6%
    212 Forest Landing Road
    Guntersville, Alabama 35976

    All Officers and Directors             8,915,000                  45.5%
    as a Group (2 people)

(1)  The  number  of shares of common stock owned are those "beneficially owned"
     as  determined  under  the rules of the Securities and Exchange Commission,
     including  any  shares  of  common  stock  as to which a person has sole or
     shared  voting or investment power and any shares of common stock which the
     person  has the right to acquire within 60 days through the exercise of any
     option,  warrant  or  right.  As of January 13, 2004, there were 19,499,364
     shares  of  common  stock  outstanding.

(2)  Includes 112,500 shares of common stock that Mr. Mullins will earn pursuant
     to  his  employment  agreement  with  the  Company for his service as chief
     executive  officer  which are issuable within approximately sixty (60) days
     of  this  report.  Mr.  Mullins  has  not  been  issued  the 112,500 shares
     discussed  as  of  the  date  of  this  report.

(3)  Includes  740,000  shares  issued  to Agricultural Research Group, of which
     Darrell  Good the Company's President is a beneficial owner, 795,000 shares
     issued  to  Cheryl  Good,  the  wife  of Darrell Good, and 1,080,000 shares
     issued  to  the  six  children  of  Mr.  Good  and  his wife, collectively.

CHANGES IN CONTROL

The Company does not anticipate any changes in control of the Company.

ITEM 12. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS

During 2003, the Company's subsidiary's former office was located in the home of
its  President.  The  President has not charged the Company rent for this space.
The  Company  reported  $3,000 of rent expense for the years ended September 30,
2003  and  2002  for  use  of  the  office  space.

                                      -18-
<PAGE>

The  Company  has $7,403  of  notes  payable  to Darrell Good, the Company's
President,  at  a  rate  of  10%  per  annum.

The  Company  has $3,235 of accounts payable to Darrell Good as of September 30,
2003.

Effective  April  30,  2002  the Company entered into a lease agreement with the
father  of  the president and major stockholder of the Company to lease 33 acres
of  land  in  Rosebud,  Texas to be used in the production of raw materials. The
lease  payments  are  $250  per month for ten years. As of September 30, 2003 no
lease  payments  were made and included in accounts payable is $4,250 related to
this  lease.

In  November 2003, Randy Mullins, the Company's Chief Executive Officer received
50,000  shares  for  cancellation  of  a  note.

In  December 2003, Randy Mullins, the Company's Chief Executive Officer received
450,000  shares  for  joining  the  Company.

In  January  2004, Randy Mullins, the Company's Chief Executive Officer received
187,500  shares  in  consideration for services rendered pursuant to his
employment  contract, as amended.

The  Agricultural Research Group (hereinafter "ARG"), of which Darrell Good, the
Company's  President,  is  a beneficial owner, is planning to supply the Company
with  raw  materials  for  the  Company's  products.

ITEM 13. EXHIBITS AND REPORTS ON FORM 8-K

     (a)  EXHIBITS

Exhibit No.           Description of Exhibit
----------            ----------------------
2.1                  Articles of Merger                      (2)

2.2                  Plan of Merger                          (2)

2.3                  Exchange Agreement                      (3)

3.1                  Articles of Amendment to Articles of
                     Incorporation                           (1)

3.2                  Articles of Incorporation               (2)

3.3                  Articles of Amendment to Articles of
                     Incorporation                           (2)

3.4                  Articles of Amendment to Articles of
                     Incorporation                           (2)

3.5                  Bylaws                                  (2)

10.1                 Employment Agreement between Randy
                     Mullins and AGTsports, Inc.             (1)

                                      -19-
<PAGE>

10.2                 Employment Agreement between Darrell
                     Good and HealthRenu Medical, Inc.        *

10.3                 Amended Employment Agreement between
                     Randy Mullins and Healthrenu Medical,
                     Inc. (formerly AGTsports, Inc.)          *

10.4                 Consulting Agreement between Rob
                     Prokos and Health Renu Medical, Inc.    (5)

10.5                 Consulting Agreement between Greg
                     Lemon and Health Renu Medical, Inc.     (5)

10.6                 Consulting Agreement between Michael
                     McClere and Health Renu Medical, Inc.   (5)

15.1                 Letter from Brimmer, Burek and Keelan,
                     LLP, Certified Public Accountants       (4)

31                   Certification of the Chief Executive
                     Officer and Chief Financial Officer
                     pursuant to Section 302 of the Sarbanes-
                     Oxley Act of 2002                        *

32                   Certification of the Chief Executive
                     Officer and Chief Financial Officer
                     pursuant to Section 906 of the Sarbanes-
                     Oxley Act of 2002                        *

(1)  Filed  as  Exhibits  3.1  and 10.1 to the Company's Form 8-K filed with the
     Securities  and  Exchange  Commission  on  August 6, 2003, and incorporated
     herein  by  reference.

(2)  Filed as Exhibits 2.1, 2.2, 3.1, 3.2, 3.3 and 3.4 to the Company's Form 8-K
     filed  with  the  Securities and Exchange Commission on September 15, 2003,
     and  incorporated  herein  by  reference.

(3)  Filed  as  Exhibit  2.1 to the Company's Form 8-K filed with the Securities
     and  Exchange  Commission  on September 29,2003, and incorporated herein by
     reference.

(4)  Filed  as  Exhibit 15.1 to the Company's Form 8-K filed with the Securities
     and  Exchange  Commission  on  February 19, 2003 and incorporated herein by
     reference.

(5)  Filed as Exhibits 10.1, 10.2, 10.3, 10.4 and 10.5 to the Company's Form S-8
     filed  with  the  Securities  and  Exchange Commission on November 26, 2003

*     Filed herein

                                      -20-
<PAGE>

     (b)  REPORTS ON FORM 8-K

The Company filed the following three reports on Form 8-K during the last
quarter of the fiscal period covered by this report:

(1)  Form  8-K  filed  on August 6, 2003, to report the appointment of a new CEO
     and  Chairman,  the  resignation of directors and officers, an amendment to
     the  articles  of incorporation to authorize 500,000 shares of Series 2003A
     Preferred  Stock,  and  the issuance of the such preferred stock to the new
     CEO  and  Chairman.

(2)  Form 8-K filed on September 18, 2003, to report a parent/subsidiary merger,
     an amendment to the articles of incorporation regarding a name change and a
     reverse stock split, and new trading symbol for the Company's common stock.

(3)  Form  8-K  filed  on September 29, 2003, authorization of a reverse merger,
     the  resignation and appointment of officers and directors, amended bylaws,
     and  the  intent  of  a  name  change

The Company filed the following two reports on Form 8-K subsequent to the last
quarter of the fiscal period covered by this report:

(4)  Form  8-K  filed  on October 30, 2003, to dismiss the former accountant and
     appoint  a  new  principal  independent  public  accountant.

(5)  Form  8-K/A  filed  on  November  26,  2003, to amend the Form 8-K filed on
     September 29, 2003, to report audited financial information of Health Renu,
     Inc,  a  wholly-owned  subsidiary.  The Company provided an audited balance
     sheet  of  Health  Renu,  Inc.  as  of September 30, 2002 and 2001, and the
     related  statement  of  operations, stockholders' equity and cash flows for
     the  years then ended as well as the Company's unaudited pro-forma combined
     balance  sheet  as  of  the  nine-month  period ended June 30, 2003 and the
     fiscal  year  September  30,  2002, as if the reverse merger, which was not
     completed  until  September 2003, had been completed as of those dates, and
     the  unaudited  pro-forma  combined  statement of operations, stockholders'
     equity  and  cash flows for the periods then ended as if the reverse merger
     had  occurred  at  the  beginning  of  those  periods.

ITEM 14. PRINCIPAL ACCOUNTANT FEES AND SERVICES

AUDIT FEES

The  aggregate fees billed for each of the fiscal years ended September 30, 2003
and  2002 for professional services rendered by the principal accountant for the
audit  of  the  Company's  annual  financial  statements was $17,346 and $4,093,
respectively.  The  aggregate  fees  billed  for  each of the fiscal years ended
September  30, 2003 and 2002 for professional services rendered by the principal
accountant  for  review of the financial statements included in the registrant's
Form  10-QSB  or  for  services  that are normally provided by the accountant in
connection with statutory and regulatory filings or engagements for those fiscal
years  was  $1,625.

AUDIT RELATED FEES

None

TAX FEES

None

                                      -21-
<PAGE>

ALL OTHER FEES

The  aggregate fees billed for each of the fiscal years ended September 30, 2003
and  2002  for products and services provided by the principal accountant, other
than  the  services  reported  above  was  $3,425.


                                   SIGNATURES

     In  accordance  with  Section 13 or 15(d) of the Securities Exchange Act of
1934,  the  Registrant  caused  this  report  to  be signed on its behalf by the
undersigned,  thereunto  duly  authorized.


                                            HEALTHRENU MEDICAL, INC.

DATED: January 13, 2004                    By: /s/ Randy Mullins
                                             ------------------------
                                             Randy Mullins
                                             Chief Executive Officer and
                                             Chief Financial Officer


     In accordance with the Securities Exchange Act of 1934, this report has
been signed below by the following persons on behalf of the Registrant and in
the capacities and on the dates indicated.

NAME                      TITLE                          DATE

/s/ Randy Mullins         Chief Executive Officer        January 13, 2004
----------------------    and Director
Randy Mullins            (Principal Executive Officer)


/s/ Randy Mullins         Chief Financial Officer        January 13, 2004
----------------------    and Director
Randy Mullins            (Principal Financial Officer)

                                      -22-
<PAGE>

Exhibit 10.2



                              EMPLOYMENT AGREEMENT


     This Employment Agreement ("Agreement") is made and effective this 1st day
of November 2003, by and between HealthRenu Medical, Inc., a Nevada corporation,
and any successor corporation (the "Company") and Darrell Good (the "Employee").

     WHEREAS, the Company recognizes the Employee's potential or future
contribution to the growth and success of the Company and desires to provide for
his continued employment by reinforcing and encouraging his continued attention
and dedication to the Company; and

     WHEREAS, the Company wishes to retain Employee's services and access to the
Employee's experience and knowledge; and

     WHEREAS, the Employee wishes to furnish services to the Company upon the
terms, provisions and conditions herein provided; and

     WHEREAS, the Employee is willing to commit himself to continue to serve as
an Employee of the Company on the terms and conditions herein provided;

     NOW, THEREFORE, in consideration of the foregoing and the agreements
hereinafter contained, the parties hereby agree as follows:

1.   Recitals.  The  "Whereas"  clauses recited above are hereby incorporated by
     reference  as  though  they  were  fully  set  forth  herein.

     2.  Employment.  The Company hereby agrees to initially employ the Employee
as  its  President  and  as  a  Director  and  the  Employee hereby accepts such
employment  and  directorship in accordance with the terms of this Agreement and
the  terms  of employment applicable to regular employees of the Company. In the
event  of  any  conflict or ambiguity between the terms of this Agreement or the
terms of employment applicable to regular employees, the terms of this Agreement
shall  control.  Election  or  appointment  of  Employee  to  another  office or
position,  regardless  of  whether  such  office  or  position  is  inferior  to
Employee's  initial office or position, shall not be a breach of this Agreement.

3.   Duties  of  Employee.  During  the  term  of this Agreement (as hereinafter
     defined), Employee will, upon reasonable request, serve as President of the
     Company  as  follows:

a.   Services  hereunder  shall  be  provided  as  an  employee  of the Company;

b.   Employee  may  be required to devote up to forty (40) hours per week to the
     Company;  and

c.   Employee may oversee the Company's general business matters as requested by
     the  Company.

     Employee  shall devote his entire productive time, ability and attention to
     the business of the Company and shall perform all duties in a professional,
     ethical and businesslike manner. Employee will not, during the term of this
     Agreement,  directly  or indirectly engage in any other business, either as
     an employee, employer, consultant, principal, officer, director, advisor or
     in  any  other  capacity,  either with or without compensation, without the
     prior  written  consent  of  the  Company.

<PAGE>

4.   Compensation.  Beginning  November  1,  2003,  the  Employee  will  be paid
     compensation  as  follows:

a.   A  base  salary  of  $7,000  (Seven  Thousand  Dollars)  per  month.

b.   The  Company  agrees,  at  its  option  and  when feasible, to institute an
     Executive Compensation Plan which may include the following: a stock option
     plan,  a  bonus plan and a deferred compensation plan. Participation in any
     or all of these plans (plus any future Executive Compensation Plans) are at
     the  sole  discretion  of  the  Board  of  Directors.

5.   Benefits.

a.   Holidays.  Employee  will be entitled to at least eleven (11) paid holidays
     and  five  (5)  personal  days  each calendar year. The Company will notify
     Employee  on  or  about the beginning of each calendar year with respect to
     the  holiday schedule for the upcoming year. Personal days, if any, will be
     scheduled  in  advance  subject  to  the  requirements of the Company. Such
     personal  days must be taken during the calendar year and cannot be carried
     forward  into  the  next  year.

b.   Vacation.  After six (6) months of continuous employment, Employee shall be
     entitled  to  three  (3)  weeks  of  paid  vacation  each  year.

c.   Sick  Leave.  Employee  shall be entitled to sick leave and emergency leave
     according to the regular policies and procedures of the Company. Additional
     sick  leave  or  emergency  leave over and above paid leave provided by the
     Company,  if any, shall be unpaid and shall be granted at the discretion of
     the  board  of  directors  of  the  Company.

d.   Medical  Insurance.  The  Employee  and his dependents (eligible to receive
     coverage)  shall  be  entitled  to  participate  in  the  Company's  health
     insurance  program.  The  Company shall pay premiums for said insurance for
     the  Employee  and  any dependents eligible to receive coverage under plans
     adopted by the Company, if any, pursuant to the Company's policies for said
     insurance.  In  addition  to  paying the premiums for medical insurance for
     Employee  and  his dependents, the Company shall reimburse Employee for all
     medical  expenses  incurred  out  of pocket, with the exception of elective
     medical  procedures  or  treatment.

e.   Pension and Profit Sharing Plans. Employee shall be entitled to participate
     in  any pension or profit sharing plan or other type of plan adopted by the
     Company  for  the  benefit  of  its  officers  and/or  regular  employees.

f.   Expense  Reimbursement. Employee shall be entitled to reimbursement for all
     reasonable  expenses,  including  travel  and  entertainment,  incurred  by
     Employee  in  the  performance of Employee's duties. Employee will maintain
     records  and  written  receipts  as  required  by  the  Company  policy and
     reasonably  requested  by  the  board  of  directors  to  substantiate such
     expenses.

6.   Term.  The term of this Agreement (the "Term") shall begin November 1, 2003
     and  end  on  October  31,  2004. The term shall be for twelve (12) months.
     Thereafter, the Agreement shall be renewed upon the mutual agreement of the
     Employee  and  the Company. If the Company fails to renew the contract, for
     reasons  other  than  cause,  the  Employee  is  entitled to six (6) months
     compensation  at  the  rate  in  effect  at the time of the non renewal. If
     Employee  fails to renew, then Employee is bound by the terms of Section 9.

<PAGE>

     In  the  event  the  Company is acquired or is the non-surviving party in a
     merger,  or  sells  all  or substantially all of its assets, this Agreement
     shall  remain  in  full  force  and  effect.

7.   Termination  by  the  Company.

a.   With  Cause. The Company may terminate the Employee's employment under this
     Agreement  at  any time for cause. For purposes of this Agreement, the term
     "cause"  shall  include  one  or  more of the following: (i) misconduct and
     failure  by  the  Employee  to  observe  or  perform  any of his duties, as
     contemplated  in  this  Agreement,  as Employee; (ii) conviction of a crime
     involving  moral  turpitude,  theft,  embezzlement or continuing alcohol or
     drug  abuse;  (iii)  fraudulent  conduct  by  the  Employee  or  any act of
     dishonesty  in connection with the Company's business; or (iv) unauthorized
     competition  with the Company, including the unauthorized use or disclosure
     of  trade  secrets, confidential or proprietary business information or the
     substantial  breach  of  any  material  covenants.  It  is  understood  and
     acknowledged by the Company that the Company shall provide thirty (30) days
     written  notice  to  Employee for those items referenced in (i), (iii), and
     (iv)  above  specifying  the  cause for termination and provide Employee an
     opportunity  to  cure  such default before such default will serve as cause
     for  termination.

     In  the event of termination for cause, the Employee shall only be entitled
     to  receive  base  salary  or benefits set forth in Section 4 and Section 5
     hereof,  through  the  date  of  termination.

8.   Confidential  Information  and  Trade  Secrets.  During  the  term  of this
     Agreement and thereafter, the Employee shall not, except as may be required
     to  perform  his duties hereunder or as required by applicable law or court
     order,  disclose  to  others  for  use, whether directly or indirectly, any
     Confidential  Information  regarding the Company. The Employee acknowledges
     that  such Confidential Information is specialized, unique in nature and of
     great  value  to the Company, and that such information gives the Company a
     competitive advantage. Upon the termination of his employment, the Employee
     will promptly deliver to the Company all documents maintained in any format
     (including  electronic  or  print) and all copies thereof in his possession
     which  contain  any  Confidential  Information.

     The  Employee  agrees  that  all  styles, designs, lists, materials, books,
     files,  reports,  correspondence,  records,  and  other documents ("Company
     Material") used, developed or prepared by, provided to or made available to
     the  Employee,  shall be and shall remain the property of the Company. Upon
     the  termination of his employment and/or the expiration of this Agreement,
     all  Company  Materials  shall  be returned immediately to the Company, and
     Employee  shall  not  make  or  retain  any  copies  thereof.  The Employee
     understands  and  agrees that in the course of employment with the Company,
     the  Employee  will  obtain access to and/or acquire Company trade secrets,
     including  Confidential  Information  which  are solely the property of the
     Company.  Therefore,  to  protect such trade secrets, the Employee promises
     and  agrees that during the term of this Agreement, and for a period of one
     (1)  year  thereafter,  he  will  not  influence  or  attempt  to influence
     employees, customers, vendors, landlords or suppliers of the Company or any
     party  in  contract with the Company providing any services to the Company,
     either directly or indirectly, to divert their employment or business to or
     with any individual, partnership, firm, corporation or other entity then in
     competition  with  the  business  of  the  Company.

<PAGE>

     "Confidential  Information"  shall  mean information about the Company, the
     Company's  respective  clients  and  customers, and proprietary information
     that  is  not  available  to  the  general  public  and that was learned or
     developed  by  the Employee or developed, used or planned to be used by the
     Company during the term of Employee's employment by the Company, including,
     without  limitation,  any data, formulae, methods, information, proprietary
     knowledge,  trade  secrets,  client  and  customer  lists  and  all papers,
     resumes,  records  and  other  documents  containing  such  Confidential
     Information.

9.   Non-Competition Covenant. Except as otherwise provided herein, the Employee
     agrees  that  during the term of this Agreement and for a period of one (1)
     year  after  the  termination  of  this  Agreement, he will not directly or
     indirectly,  without  the  prior  written  consent  of the Company, provide
     general  business  services  with  or without pay, or own, manage, operate,
     join,  control,  participate in, or be connected as a stockholder, partner,
     or otherwise, with any business, individual, partner, firm, corporation, or
     other  entity  which  is  in  competition  with  the  Company.

10.  Notices.  For the purpose of this Agreement, notices, demands and all other
     communications provided for in this Agreement shall be in writing and shall
     be  deemed to have been duly given when delivered personally, or by private
     overnight  courier  or  mail services, postage prepaid or (unless otherwise
     specified)  mailed  by  United  States registered or certified mail, return
     receipt  requested,  postage  prepaid,  and  addressed  as  follows:

If to Company:     HealthRenu Medical, Inc.
                   307 South Friendswood Drive, Suite E-1
                   Friendswood, Texas 77546

If to Employee:    Darrell Good
                  [ADDRESS]


11.  Modification.  No  modification,  change,  addition,  rescission,  release,
     amendment  or  waiver  of  this  Agreement  and  no  approval,  consent, or
     authorization  required  by any provision of this Agreement, may be made by
     any  person  except  by a written agreement by a duly authorized officer or
     partner  of  the  Company  and  the  Employee.

<PAGE>

12.  Waiver.  No  delay,  waiver, omission or forbearance (whether by conduct or
     otherwise)  by  any party hereto at any time to exercise any right, option,
     duty or power arising out of breach or default by the other party of any of
     the  terms,  conditions, or provisions of this Agreement to be performed by
     such  other  party  shall  constitute a waiver by such party or a waiver of
     such  party's  rights  to enforce any right, option or power as against the
     other  party or as to subsequent breach or default by such other party, and
     no  explicit  waiver  shall  constitute  a  waiver of similar or dissimilar
     terms,  provisions  or  conditions,  at  the  same  time or at any prior or
     subsequent  time.

13.  Cumulative  Rights.  The rights of the Company hereunder are cumulative and
     no  exercise or enforcement by the Company of any right or remedy hereunder
     will preclude the exercise or enforcement by the Company of any other right
     or  remedy  hereunder  or  which the Company is entitled by law to enforce.

14.  No  Assignment.  The  right  of the employee or any other beneficiary under
     this  Agreement  to  receive  payments  may  not  be  assigned,  pledged or
     encumbered,  except  by  will  or  by the laws of descent and distribution,
     without the permission of the Company which it may withhold in its sole and
     absolute  discretion.

15.  Review  of Agreement. The Employee has had full and adequate opportunity to
     read  and  review  this Agreement and to be thoroughly advised of the terms
     and  conditions  of  this  Agreement  by  an  attorney  or  other  personal
     representative.

16.  Binding  Agreement. This Agreement and all rights of the Employee hereunder
     shall inure to the benefit of and be enforceable by the Employee's personal
     or  legal  representatives,  executors,  administrators, successors, heirs,
     distributes,  devisees  and  legatees.  In addition, this Agreement and the
     obligations  and  rights  of  the Company hereunder shall be binding on any
     person,  firm,  or  corporation  which  is  a  successor-in-interest to the
     Company.

17.  Final  Agreement.  This  Agreement  supersedes  and  terminates  all  prior
     agreements,  either  oral or in writing, between the parties and therefore,
     representations,  inducements, promises or agreements alleged by either the
     Company  or  the Employee that are not contained in this Agreement will not
     be  enforceable.  There  are  no  other  oral  or written understandings or
     agreements  between  the  Company  and the Employee relating to the subject
     matter  of  this  Agreement.  This Agreement will not supersede any written
     agreements  or  contracts that are signed concurrently with this Agreement.

18.  Governing Law. This Agreement shall be construed and enforced in accordance
     with  the  laws  of  the  State  of  Texas.

19.  Headings. Headings used in this Agreement are provided for convenience only
     and  shall  not  be  used  to  construe  meaning  or  intent.

<PAGE>

20.  Number  and  Gender.  Whenever used, the singular shall include the plural,
     the  plural  the singular, and the use of any gender shall be applicable to
     all  genders.

21.  Counterparts.  This  Agreement may be executed in one or more counterparts,
     each  of  which shall be deemed to be an original but all of which together
     will  constitute  one  and  the  same  instrument.

22.  Severability.  All  provisions  of  this  Agreement  are severable and this
     Agreement  will be interpreted and enforced as if all completely invalid or
     unenforceable  provisions were not contained herein and partially valid and
     enforceable  provisions  will  be  enforced  to  the  extent  valid  and
     enforceable.  If  any applicable law or rule of any jurisdiction requires a
     greater  prior notice of the termination of this Agreement than is required
     hereunder  or the taking of some other action not required hereunder, or if
     under any applicable law or rule of any jurisdiction, any provision of this
     Agreement  or any specification, standard or operating procedure prescribed
     by  the  Company  is invalid or unenforceable under applicable law then the
     prior  notice  or  other  action  required  by  such  law  or  rule will be
     substituted  for  the  notice  requirements  hereof,  or  such  invalid  or
     unenforceable  provision,  specification,  standard  or operating procedure
     will  be  modified to the extent required to be valid and enforceable. Such
     modifications  to  this  Agreement  will  be  effective  only  in  such
     jurisdiction.

23.  Arbitration.  The  parties  agree  that they will use their best efforts to
     amicably  resolve any dispute arising out of or relating to this Agreement.
     Any  controversy,  claim,  or  dispute  that cannot be so resolved shall be
     settled  by  final  binding arbitration in accordance with the rules of the
     American  Arbitration  Association  and judgment upon the award rendered by
     the  arbitrator(s) may be entered in any court having jurisdiction thereof.
     Any  such  arbitration  shall  be conducted in Harris County, Texas or such
     other  place  as may be mutually agreed upon by the parties. Within fifteen
     (15)  days  after  the  commencement  of  the arbitration, each party shall
     select one person to act as arbitrator, and the two arbitrators so selected
     shall  select a third arbitrator within ten (10) days of their appointment.
     Each  party  shall  bear  an  equal  share of the arbitrator's expenses and
     administrative  fees  of  arbitration, and the losing party shall reimburse
     the  winning  party for attorney's fees, arbitrator fees, and any other out
     of  pocket  expenses.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date first above written.


HEALTHRENU MEDICAL, INC.

By: /s/ Randy Mullins
   ----------------------------
Its: Chief Executive Officer


EMPLOYEE
    /s/ Darrell Good
   ----------------------------
   Darrell Good
   Employee


<PAGE>

Exhibit 10.3



                     Amendment No. 1 to EMPLOYMENT AGREEMENT


     This  Employment Agreement ("Agreement") is made and effective this 1st day
of  August  2003,  by  and  between  HealthRenu  Medical,  Inc.,  Inc., a Nevada
corporation,  formerly  AGTSports,  Inc.  and  any  successor  corporation  (the
"Company")  and  Randy  Mullins  (the "Employee"). This Agreement supercedes the
previous  employment  agreement  between  Mullins  and  AGTSports,  Inc.

     WHEREAS,  the  Company  recognizes  the  Employee's  potential  or  future
contribution to the growth and success of the Company and desires to provide for
his  continued employment by reinforcing and encouraging his continued attention
and  dedication  to  the  Company;  and

     WHEREAS, the Company wishes to retain Employee's services and access to the
Employee's  experience  and  knowledge;  and

     WHEREAS,  the  Employee wishes to furnish executive services to the Company
upon  the  terms,  provisions  and  conditions  herein  provided;  and

     WHEREAS,  the Employee is willing to commit himself to continue to serve as
an  Employee  of  the  Company  on  the  terms  and  conditions herein provided;

     NOW,  THEREFORE,  in  consideration  of  the  foregoing  and the agreements
hereinafter  contained,  the  parties  hereby  agree  as  follows:

1.   Recitals.  The  "Whereas"  clauses recited above are hereby incorporated by
     reference  as  though  they  were  fully  set  forth  herein.

2.   Employment.  The  Company hereby agrees to initially employ the Employee as
     its Chief Executive Officer and the Employee hereby accepts such employment
     in  accordance with the terms of this Agreement and the terms of employment
     applicable  to  regular  employees  of  the  Company.  In  the event of any
     conflict  or  ambiguity between the terms of this Agreement or the terms of
     employment  applicable  to  regular  employees, the terms of this Agreement
     shall  control.  Election  or  appointment of Employee to another office or
     position,  regardless  of  whether  such  office or position is inferior to
     Employee's  initial  office  or  position,  shall  not  be a breach of this
     Agreement.

3.   Duties  of  Employee.  During  the  term  of this Agreement (as hereinafter
     defined),  Employee will, upon reasonable request, serve as Chief Executive
     Officer  of  the  Company  as  follows:

a.   Services  hereunder  shall  be  provided  as  an  employee  of the Company;

b.   Employee  may  be required to devote up to forty (40) hours per week to the
     Company;  and

c.   Employee  may  oversee  the  Company's  executive, financial and accounting
     matters  as  requested  by  the  Company.

     Employee  shall devote his entire productive time, ability and attention to
     the business of the Company and shall perform all duties in a professional,
     ethical and businesslike manner. Employee will not, during the term of this
     Agreement,  directly  or indirectly engage in any other business, either as
     an employee, employer, consultant, principal, officer, director, advisor or
     in  any  other  capacity,  either with or without compensation, without the
     prior  written  consent  of  the  Company.

<PAGE>

4.   Compensation.  Beginning  September  15,  2003,  the  Employee will be paid
     compensation  as  follows:

a.   A  base  salary  of  $72,000 (Seventy-Two Thousand Dollars) per year, after
     which time the Company will review and may increase such salary or maintain
     the  status  quo.

b.   As  additional consideration for signing this Agreement and for agreeing to
     abide  and  be  bound  by  its  terms,  provisions  and restriction, and in
     addition  to all other benefits described in this Agreement, Employee shall
     receive  shares of restricted Company common stock (the "Shares") according
     to  the  following  terms:  450,000  shares  upon signing of the employment
     agreement  and  37,500  shares  per  month for each full month services are
     provided  by Employee to the Company, subject to cancellation, in whole are
     in  specified  part,  by  the Board of Directors of the Company in its sole
     discretion,  until  such  time as Employee receives an aggregate of 450,000
     shares  of Company common stock provided that the Board of Directors of the
     Company  has  not  previously  exercised  its  discretion  to  cancel  such
     additional  consideration.  The  Shares  shall  be  issued and delivered to
     Employee  on  a  monthly  basis.  The  Company  grants  Employee piggy-back
     registration rights and agrees to register the resale of Shares received by
     the Employee pursuant to this Agreement on the first registration statement
     filed  by  the  Company.

c.   The  Company  agrees,  at  its  option  and  when feasible, to institute an
     Executive Compensation Plan which may include the following: a stock option
     plan,  a  bonus plan and a deferred compensation plan. Participation in any
     or all of these plans (plus any future Executive Compensation Plans) are at
     the  sole  discretion  of  the  Board  of  Directors.

5.   Exemption  from Registration. The Shares have not been registered under the
     Securities  Act  of  1933,  as  amended, and certificates representing same
     shall  bear  the  following  restrictive  legend:

     "The  securities  represented  by this certificate have not been registered
     under  the  Securities  Act  of  1933,  as  amended,  or  applicable  state
     securities  laws, and may not be sold, transferred, pledged or hypothecated
     without  either:  i)  registration  under  the  Securities  Act of 1933, as
     amended,  and  applicable  state  securities laws, or ii) submission to the
     Company  of  an  opinion  of counsel, satisfactory to the Company that said
     securities  and  the  transfer  thereof  are  exempt  from the registration
     requirements  of the Securities Act of 1933 and applicable state securities
     laws."

<PAGE>

6.   Benefits.

a.   Holidays.  Employee  will be entitled to at least eleven (11) paid holidays
     and  five  (5)  personal  days  each calendar year. The Company will notify
     Employee  on  or  about the beginning of each calendar year with respect to
     the  holiday schedule for the upcoming year. Personal days, if any, will be
     scheduled  in  advance  subject  to  the  requirements of the Company. Such
     personal  days must be taken during the calendar year and cannot be carried
     forward  into  the  next  year.

b.   Vacation.  Upon  signing,  Employee shall be entitled to three (3) weeks of
     paid  vacation  each  year.

c.   Sick  Leave.  Employee  shall be entitled to sick leave and emergency leave
     according to the regular policies and procedures of the Company. Additional
     sick  leave  or  emergency  leave over and above paid leave provided by the
     Company,  if any, shall be unpaid and shall be granted at the discretion of
     the  board  of  directors  of  the  Company.

d.   Medical  Insurance.  The  Employee  and his dependents (eligible to receive
     coverage)  shall  be  entitled  to  participate  in  the  Company's  health
     insurance  program.  The  Company shall pay premiums for said insurance for
     the  Employee  and  any dependents eligible to receive coverage under plans
     adopted by the Company, if any, pursuant to the Company's policies for said
     insurance.  In  addition  to  paying the premiums for medical insurance for
     Employee  and  his dependents, the Company shall reimburse Employee for all
     medical  expenses  incurred  out  of pocket, with the exception of elective
     medical  procedures  or  treatment.

e.   Pension and Profit Sharing Plans. Employee shall be entitled to participate
     in  any pension or profit sharing plan or other type of plan adopted by the
     Company  for  the  benefit  of  its  officers  and/or  regular  employees.

f.   Expense  Reimbursement. Employee shall be entitled to reimbursement for all
     reasonable  expenses,  including  travel  and  entertainment,  incurred  by
     Employee  in  the  performance of Employee's duties. Employee will maintain
     records  and  written  receipts  as  required  by  the  Company  policy and
     reasonably  requested  by  the  board  of  directors  to  substantiate such
     expenses.

g.   Car allowance. The Company will provide to Employee a car allowance of $750
     per  month  and  reimburse  Employee  for annual car insurance. Employee is
     responsible  for  all automobile operating expenses incurred by Employee in
     the  performance  of  any  of  Employee's  Company  duties.

7.   Term.  The  term  of  this Agreement (the "Term") shall begin September 15,
     2003  and  end  on  September  30,  2004. The term shall be for twelve (12)
     months.  Thereafter,  the  Agreement  shall  be  renewed  upon  the  mutual
     agreement  of  the  Employee and the Company. If the Company fails to renew
     the contract, for reasons other than cause, the Employee is entitled to six
     (6)  months  compensation  at  the  rate  in  effect at the time of the non
     renewal. If Employee fails to renew, then Employee is bound by the terms of
     section  10.

     In  the  event  the  Company is acquired or is the non-surviving party in a
     merger,  or  sells  all  or substantially all of its assets, this Agreement
     shall  remain  in  full  force and effect and all Shares will be treated as
     earned  by  Employee.

<PAGE>

8.   Termination  by  the  Company.

a.   With  Cause. The Company may terminate the Employee's employment under this
     Agreement  at  any time for cause. For purposes of this Agreement, the term
     "cause"  shall  include  one  or  more of the following: (i) misconduct and
     failure  by  the  Employee  to  observe  or  perform  any of his duties, as
     contemplated  in  this  Agreement,  as Employee; (ii) conviction of a crime
     involving  moral  turpitude,  theft,  embezzlement or continuing alcohol or
     drug  abuse;  (iii)  fraudulent  conduct  by  the  Employee  or  any act of
     dishonesty  in connection with the Company's business; or (iv) unauthorized
     competition  with the Company, including the unauthorized use or disclosure
     of  trade  secrets, confidential or proprietary business information or the
     substantial  breach  of  any  material  covenants.  It  is  understood  and
     acknowledged by the Company that the Company shall provide thirty (30) days
     written  notice  to  Employee for those items referenced in (i), (iii), and
     (iv)  above  specifying  the  cause for termination and provide Employee an
     opportunity  to  cure  such default before such default will serve as cause
     for  termination.

     In  the event of termination for cause, the Employee shall only be entitled
     to  receive  base  salary  or benefits set forth in Section 4 and Section 6
     hereof,  through  the  date  of  termination.

b.   Effect  of Termination. In the event this Agreement is terminated for cause
     by  the  Company  or  Employee  shall resign, Employee shall be entitled to
     maintain  the  450,000  shares  issued  upon  the signing of the employment
     agreement  and  37,500  Shares of the Shares issued to Employee pursuant to
     Section  4(b) hereof for each full month in which services were provided by
     Employee  and  the  Board  of  Directors  in  its  sole  discretion had not
     previously  cancelled  such  additional  consideration.

9.   Confidential  Information  and  Trade  Secrets.  During  the  term  of this
     Agreement and thereafter, the Employee shall not, except as may be required
     to  perform  his duties hereunder or as required by applicable law or court
     order,  disclose  to  others  for  use, whether directly or indirectly, any
     Confidential  Information  regarding the Company. The Employee acknowledges
     that  such Confidential Information is specialized, unique in nature and of
     great  value  to the Company, and that such information gives the Company a
     competitive advantage. Upon the termination of his employment, the Employee
     will promptly deliver to the Company all documents maintained in any format
     (including  electronic  or  print) and all copies thereof in his possession
     which  contain  any  Confidential  Information.

     The  Employee  agrees  that  all  styles, designs, lists, materials, books,
     files,  reports,  correspondence,  records,  and  other documents ("Company
     Material") used, developed or prepared by, provided to or made available to
     the  Employee,  shall be and shall remain the property of the Company. Upon
     the  termination of his employment and/or the expiration of this Agreement,
     all  Company  Materials  shall  be returned immediately to the Company, and
     Employee  shall  not  make  or  retain  any  copies  thereof.  The Employee
     understands  and  agrees that in the course of employment with the Company,
     the  Employee  will  obtain access to and/or acquire Company trade secrets,
     including  Confidential  Information  which  are solely the property of the
     Company.  Therefore,  to  protect such trade secrets, the Employee promises
     and  agrees that during the term of this Agreement, and for a period of one
     (1)  year  thereafter,  he  will  not  influence  or  attempt  to influence
     employees, customers, vendors, landlords or suppliers of the Company or any
     party  in  contract with the Company providing any services to the Company,
     either directly or indirectly, to divert their employment or business to or
     with any individual, partnership, firm, corporation or other entity then in
     competition  with  the  business  of  the  Company.

<PAGE>

     "Confidential  Information"  shall  mean information about the Company, the
     Company's  respective clients and customers, and proprietary information as
     defined  herein,  that  is not available to the general public and that was
     learned  or  developed  by the Employee or developed, used or planned to be
     used  by  the  Company  during  the  term  of  Employee's employment by the
     Company,  including,  without  limitation,  any  data,  formulae,  methods,
     information,  proprietary  knowledge,  trade  secrets,  client and customer
     lists  and all papers, resumes, records and other documents containing such
     Confidential  Information.

10.  Non-Competition Covenant. Except as otherwise provided herein, the Employee
     agrees  that  during the term of this Agreement and for a period of one (1)
     year  after  the  termination  of  this  Agreement, he will not directly or
     indirectly,  without  the  prior  written  consent  of the Company, provide
     executive,  financial  and  accounting  services  or other services with or
     without  pay, or own, manage, operate, join, control, participate in, or be
     connected  as  a  stockholder,  partner,  or  otherwise, with any business,
     individual,  partner,  firm,  corporation,  or  other  entity  which  is in
     competition  with  the  Company.

11.  Notices.  For the purpose of this Agreement, notices, demands and all other
     communications provided for in this Agreement shall be in writing and shall
     be  deemed to have been duly given when delivered personally, or by private
     overnight  courier  or  mail services, postage prepaid or (unless otherwise
     specified)  mailed  by  United  States registered or certified mail, return
     receipt  requested,  postage  prepaid,  and  addressed  as  follows:

If to Company:     HealthRenu Medical, Inc.
                   307 South Friendswood Drive, Suite E-1
                   Friendswood, Texas 77546

If to Employee:    Randy Mullins
                   16107 Affirmed Way
                   Friendswood, Texas 77546


12.  Modification.  No  modification,  change,  addition,  rescission,  release,
     amendment  or  waiver  of  this  Agreement  and  no  approval,  consent, or
     authorization  required  by any provision of this Agreement, may be made by
     any  person  except  by a written agreement by a duly authorized officer or
     partner  of  the  Company  and  the  Employee.

<PAGE>

13.  Waiver.  No  delay,  waiver, omission or forbearance (whether by conduct or
     otherwise)  by  any party hereto at any time to exercise any right, option,
     duty or power arising out of breach or default by the other party of any of
     the  terms,  conditions, or provisions of this Agreement to be performed by
     such  other  party  shall  constitute a waiver by such party or a waiver of
     such  party's  rights  to enforce any right, option or power as against the
     other  party or as to subsequent breach or default by such other party, and
     no  explicit  waiver  shall  constitute  a  waiver of similar or dissimilar
     terms,  provisions  or  conditions,  at  the  same  time or at any prior or
     subsequent  time.

14.  Cumulative  Rights.  The rights of the Company hereunder are cumulative and
     no  exercise or enforcement by the Company of any right or remedy hereunder
     will preclude the exercise or enforcement by the Company of any other right
     or  remedy  hereunder  or  which the Company is entitled by law to enforce.

15.  No  Assignment.  The  right  of the employee or any other beneficiary under
     this  Agreement  to  receive  payments  may  not  be  assigned,  pledged or
     encumbered,  except  by  will  or  by the laws of descent and distribution,
     without the permission of the Company which it may withhold in its sole and
     absolute  discretion.

16.  Review  of Agreement. The Employee has had full and adequate opportunity to
     read  and  review  this Agreement and to be thoroughly advised of the terms
     and  conditions  of  this  Agreement  by  an  attorney  or  other  personal
     representative.

17.  Binding  Agreement. This Agreement and all rights of the Employee hereunder
     shall inure to the benefit of and be enforceable by the Employee's personal
     or  legal  representatives,  executors,  administrators, successors, heirs,
     distributes,  devisees  and  legatees.  In addition, this Agreement and the
     obligations  and  rights  of  the Company hereunder shall be binding on any
     person,  firm,  or  corporation  which  is  a  successor-in-interest to the
     Company.

18.  Final  Agreement.  This  Agreement  supersedes  and  terminates  all  prior
     agreements,  either  oral or in writing, between the parties and therefore,
     representations,  inducements, promises or agreements alleged by either the
     Company  or  the Employee that are not contained in this Agreement will not
     be  enforceable.  There  are  no  other  oral  or written understandings or
     agreements  between  the  Company  and the Employee relating to the subject
     matter  of  this  Agreement.  This Agreement will not supersede any written
     agreements  or  contracts that are signed concurrently with this Agreement.

19.  Governing Law. This Agreement shall be construed and enforced in accordance
     with  the  laws  of  the  State  of  Texas.

20.  Headings. Headings used in this Agreement are provided for convenience only
     and  shall  not  be  used  to  construe  meaning  or  intent.

<PAGE>

21.  Number  and  Gender.  Whenever used, the singular shall include the plural,
     the  plural  the singular, and the use of any gender shall be applicable to
     all  genders.

22.  Counterparts.  This  Agreement may be executed in one or more counterparts,
     each  of  which shall be deemed to be an original but all of which together
     will  constitute  one  and  the  same  instrument.

23.  Severability.  All  provisions  of  this  Agreement  are severable and this
     Agreement  will be interpreted and enforced as if all completely invalid or
     unenforceable  provisions were not contained herein and partially valid and
     enforceable  provisions  will  be  enforced  to  the  extent  valid  and
     enforceable.  If  any applicable law or rule of any jurisdiction requires a
     greater  prior notice of the termination of this Agreement than is required
     hereunder  or the taking of some other action not required hereunder, or if
     under any applicable law or rule of any jurisdiction, any provision of this
     Agreement  or any specification, standard or operating procedure prescribed
     by  the  Company  is invalid or unenforceable under applicable law then the
     prior  notice  or  other  action  required  by  such  law  or  rule will be
     substituted  for  the  notice  requirements  hereof,  or  such  invalid  or
     unenforceable  provision,  specification,  standard  or operating procedure
     will  be  modified to the extent required to be valid and enforceable. Such
     modifications  to  this  Agreement  will  be  effective  only  in  such
     jurisdiction.

24.  Arbitration.  The  parties  agree  that they will use their best efforts to
     amicably  resolve any dispute arising out of or relating to this Agreement.
     Any  controversy,  claim,  or  dispute  that cannot be so resolved shall be
     settled  by  final  binding arbitration in accordance with the rules of the
     American  Arbitration  Association  and judgment upon the award rendered by
     the  arbitrator(s) may be entered in any court having jurisdiction thereof.
     Any  such  arbitration  shall  be conducted in Harris County, Texas or such
     other  place  as may be mutually agreed upon by the parties. Within fifteen
     (15)  days  after  the  commencement  of  the arbitration, each party shall
     select one person to act as arbitrator, and the two arbitrators so selected
     shall  select a third arbitrator within ten (10) days of their appointment.
     Each  party  shall  bear  an  equal  share of the arbitrator's expenses and
     administrative  fees  of  arbitration, and the losing party shall reimburse
     the  winning  party for attorney's fees, arbitrator fees, and any other out
     of  pocket  expenses.

IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
date first above written.


HEALTHRENU MEDICAL, INC.

By: /s/ Darrell Good
   -----------------------------
Its: President and Founder
   -----------------------------


EMPLOYEE

   /s/ Randy Mullins
   -----------------------------
   Randy Mullins
   Employee

<PAGE>

Exhibit 31


                                  CERTIFICATION

I, Randy Mullins, certify that:

1.   I  have  reviewed  this annual report on Form 10-KSB of HealthRenu Medical,
     Inc.;

2.   Based on my knowledge, this report does not contain any untrue statement of
     a  material  fact  or  omit  to state a material fact necessary to make the
     statements  made, in light of the circumstances under which such statements
     were  made,  not  misleading  with  respect  to  the period covered by this
     report;

3.   Based  on  my  knowledge,  the  financial  statements,  and other financial
     information  included  in  this  report,  fairly  present  in  all material
     respects  the  financial condition, results of operations and cash flows of
     HealthRenu  Medical,  Inc.  as  of,  and for, the periods presented in this
     report;

4.   I  am  responsible for establishing and maintaining disclosure controls and
     procedures  (as  defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for
     HealthRenu  Medical,  Inc.  and  have:

     a)   Designed  such  disclosure  controls  and  procedures,  or caused such
          disclosure  controls  and  procedures  to  be  designed  under  my
          supervision,  to  ensure  that  material  information  relating  to
          HealthRenu  Medical, Inc., including its consolidated subsidiaries, is
          made  known to me by others within those entities, particularly during
          the  period  in  which  this  report  is  being  prepared;

     b)   Paragraph  omitted  in  accordance  with  SEC  transition instructions
          contained  in  SEC  Release  No.  33-8238;

     c)   Evaluated  the  effectiveness of HealthRenu Medical, Inc.'s disclosure
          controls  and  procedures  and presented in this report my conclusions
          about  the effectiveness of the disclosure controls and procedures, as
          of  the  end  of  the  period  covered  by  this  report based on such
          evaluation;  and

     d)   Disclosed  in  this  report  any  change in HealthRenu Medical, Inc.'s
          internal  control  over  financial  reporting  that  occurred  during
          HealthRenu  Medical,  Inc.'s fourth fiscal quarter that has materially
          affected,  or  is  reasonably  likely to materially affect, HealthRenu
          Medical,  Inc.'s  internal  control  over  financial  reporting;  and

5.   I  have  disclosed,  based on my most recent evaluation of internal control
     over  financial  reporting,  to HealthRenu Medical, Inc.'s auditors and the
     audit  committee  of  HealthRenu  Medical,  Inc.'s  board  of directors (or
     persons  performing  the  equivalent  functions):

     a)   All  significant deficiencies and material weaknesses in the design or
          operation  of  internal  control  over  financial  reporting which are
          reasonably  likely  to  adversely  affect  HealthRenu  Medical, Inc.'s
          ability  to  record,  process,  summarize  and  report  financial
          information;  and

     b)   Any  fraud, whether or not material, that involves management or other
          employees  who  have  a significant role in HealthRenu Medical, Inc.'s
          internal  control  over  financial  reporting.

Date:  January 13, 2004


                                   By: /s/Randy Mullins
                                   -------------------------------
                                   Randy Mullins,
                                   Chief Executive Officer and
                                   Chief Financial Officer

<PAGE>


Exhibit 32


      CERTIFICATION OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER
           PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


I,  Randy  Mullins,  certify,  pursuant  to  18  U.S.C. Section 1350, as adopted
pursuant  to  Section  906  of  the  Sarbanes-Oxley Act of 2002, that the Annual
Report  of  HealthRenu  Medical,  Inc.  on Form 10-KSB for the fiscal year ended
September  30,  2003  fully  complies  with the requirements of Section 13(a) or
15(d)  of  the Securities Exchange Act of 1934 and that information contained in
such  Form  10-KSB  fairly  presents  in  all  material  respects  the financial
condition  and  results  of  operations  of  HealthRenu  Medical,  Inc.


                                     By:/s/ Randy Mullins
                                     --------------------------
                                     Name:  Randy Mullins
                                     Title: Chief Executive Officer and
                                     Chief Financial Officer
January 13, 2004

<PAGE>